IRF5 degraders and uses thereof
Bifunctional compounds targeting IRF5 protein for degradation via E3 ubiquitin ligase recruitment address the need for specific modulation of IRF5 in autoimmune disorders, providing a therapeutic advantage over global immunosuppression.
Patent Information
- Application Number
- PCT/US2026/027425
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There is a high unmet need for drugs that can modulate interferon regulatory factor 5 (IRF5) to treat autoimmune disorders by leveraging E3 ligase-mediated protein degradation, as chronic Type I IFN response can promote autoimmunity and current treatments primarily focus on global immunosuppression.
Development of bifunctional compounds that recruit IRF5 protein to E3 ubiquitin ligase for targeted degradation, using cereblon binding moieties linked to IRF5-binding ligands, to inhibit or degrade IRF5 protein effectively.
These compounds provide a broad range of pharmacological activities for treating autoimmune disorders by specifically targeting and degrading IRF5 protein, offering a new therapeutic approach beyond global immunosuppression.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000003_0002 
Figure IMGF000004_0001
Abstract
Description
Attorney Docket No.: KME-320WO IRF5 DEGRADERS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U. S. Provisional Application No.63 / 802,466, filed May 8, 2025, which is incorporated herein by reference in its entirety.FIELD
[0002] The present disclosure relates to compounds and methods useful for the modulation of interferon regulatory factor 5 (IRF5) via ubiquitination and / or degradation by compounds and compositions disclosed herein. The present disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compositions in the treatment of various diseases.BACKGROUND
[0003] Ubiquitin-Proteasome Pathway (UPP) or Ubiquirin-Proteasome System (UPS) is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.
[0004] The UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinatc target proteins and synthetic small-molecule probes to induce proteasome-dependent degradation. Bifunctional compounds composed of a target protein- binding ligand and an E3 ubiquitin ligase ligand, induced proteasome-mediated degradation of selected proteins via their recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression. Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins (Crews, C., Chemistry & Biology, 2010, 17(6):551 -555; Schnnekloth, J. S. Jr., Chembiochem, 2005, 6(l):40-46).
[0005] Interferon regulatory factor 5 (IRF5) is a transcription factor belonging to the interferon regulatory factor family. The activation of IRF5 is dependent on both the initiating signal and the cell types involved. IRF5 produces Type I interferon (IFN) response, which is made up of interferon beta 1 (IFNB1) gene and 13 closely related interferon alpha (IFNA) genes. The activity of IRF5 downstream of various pattern recognition receptors (PRRs) determines the extent of the Type I IFN production and the pattern of cytokines induced.Page 1 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0006] Type I IFN activity is important as a line of defense against pathogens. Chronic Type I IFN response can promote autoimmunity by increasing associated antigen (Ag) presentation, lymphocyte-mediated adaptive immune responses, and chemokine expression. IRF5 has been identified as an autoimmune susceptibility gene and correlates with higherlevels of Type I IFN, tumor necrosis factor alpha (TNFa), interleukin 6 (IL6), plasmablasts, and antinuclear antibodies (ANAs). Global immunosuppression to control disease activity remains the standard of care for autoimmune disorders, and there is still a high unmet need to develop drugs against targets involved in disease progression.
[0007] As such, small molecule compounds that leverage E3 ligase mediated protein degradation to target disease-associated proteins such as IRF5 hold promise as therapeutic agents. The compounds, compositions, and methods described herein are directed toward this end.SUMMARY
[0008] The present disclosure relates to novel bifunctional compounds, which function to recruit IRF5 protein to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. In particular, the present disclosure provides bifunctional compounds, which find utility as modulators of targeted ubiquitination of IRF5 protein, which are then degraded and / or otherwise inhibited by the bifunctional compounds as described herein. Also provided are monovalent compounds, which find utility as inducers of targeted ubiquitination of IRF5 protein, which are then degraded and / or otherwise inhibited by the monovalent compounds as described herein. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation / inhibition of IRF5 protein. In addition, the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease or disorder, such as autoimmune disorders.
[0009] The present application further relates to targeted degradation of IRF5 protein through the use of bifunctional molecules, including bifunctional molecules that link a cereblon binding moiety to a ligand that binds IRF5 protein.
[0010] Compounds disclosed herein, and pharmaceutically acceptable compositions thereof, are effective as degraders of IRF5 protein.
[0011] Disclosed herein, in some embodiments, are compounds of Formula A:Page 2 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0012] Disclosed herein, in some embodiments, are compounds of Formula I:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0013] Disclosed herein, in some embodiments, are compounds of Formula II:Page 3 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0014] Compounds disclosed herein, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with inflammatory responses and / or immune pathways implicating IRF5 protein. Such diseases, disorders, or conditions include those described herein.
[0015] Compounds disclosed herein are also useful for the study of IRF5 protein in biological and pathological phenomena; the study of inflammatory responses and / or immune pathways occurring in bodily tissues; and the comparative evaluation of new IRF5 degraders, in vitro or in vivo.DETAILED DESCRIPTION
[0016] As generally described herein, the present disclosure features compounds, or pharmaceutically acceptable salts thereof (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and compositions comprising said compounds useful as degraders of IRF5 protein. Compounds and compositions disclosed herein are also useful for treating diseases or disorders.Page 4 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Definitions
[0017] As used herein, the following definitions apply to the terms as used to describe the present disclosure, unless otherwise indicated or apparent from context. Unless explicitly indicated otherwise, or apparent from context, the terms below do not exclude the meaning that the term has acquired in the art to which it pertains. The definitions below are provided to facilitate the description of the disclosure, but they are not intended to limit the scope of the disclosure.Chemical Definitions
[0018] Chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0019] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the present disclosure are within the scope of the present disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of each of one or more hydrogen atoms by deuterium or tritium, or the replacement of each of one or more carbon atoms by a13C- or14C-enriched carbon are within the scope of the present disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.
[0020] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “Ci-Ce alkyl” is intended to encompass, Ci, C2, C3, C4, C5, Ce, Ci-Ce, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and Cs-Ce alkyl.
[0021] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely Page 5 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic,”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle”) refers to a monocyclic C3-C6 hydrocarbon that is substituted or unsubstituted and is completely saturated (i.e., cycloalkyl) or that contains one or more units of unsaturation (i.e., cycloalkenyl), but which is not aromatic, that has a single point of attachment to the rest of the molecule. In some embodiments, a carbocyclic ring may be a 5-12 membered bicyclic, bridged bicyclic, or spirocyclic ring (e.g., spirocyclic carbocycle ring). A carbocyclic ring may include one or more oxo (=0) or thioxo (=S) substituent. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl) alkyl or (cycloalkyl)alkenyl. A carbocyclic ring may include one or more bridged bicyclic and / or spirocyclic ring. A carbocyclic ring may include a bridged bicyclic carbocycle and a bridged bicyclic heterocycle.
[0022] As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:Page 6 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0023] As used herein, the term “bridged bicyclic carbocycle” refers to any bicyclic carbocyclic ring system, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic carbocycle has 7-12 carbon ring members. Such bridged bicyclic carbocycles are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon atom. Unless otherwise specified, a bridged bicyclic carbocycle is optionally substituted with one or more substituents as set forth for aliphatic groups. Exemplary bridged bicyclic carbocycles
[0024] As used herein, the term “bridged bicyclic heterocycle” refers to any bicyclic heterocyclic ring system, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic heterocycle has 7-12 ring members and 1-4Page 7 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic heterocycles are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom.
[0025] Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclic heterocycles include:
[0026] As used herein, the term “spirocyclic ring” refers to a spirocyclic ring system, where two rings are connected through exactly one shared atom. In an embodiment, the shared atom is a quaternary carbon atom. In an embodiment, the shared atom is a nitrogen atom. The rings may each independently be a carbocyclic or heterocyclic ring. Each ring can be a saturated or partially unsaturated ring. In an embodiment, one ring is carbocyclic and one ring is heterocyclic. In an embodiment, the two rings are carbocyclic rings. In an embodiment, the two rings are heterocyclic rings.
[0027] As used herein, the term “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-C20 alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-C10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-C9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“Ci-Cs alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-C7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“Ci-Ce alkyl”, also referred to herein as “lower alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-C5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-C4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-C3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-C2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of C1-6 alkyl groups include, but are not limited to, methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (Cs), 3-pentanyl (Cs), amyl (Cs), neopentyl (Cs), 3-methyl-2-Page 8 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO butanyl (C.s), tertiary amyl (Cs), and n-hexyl (Ce). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like. Unless otherwise specified, each instance of an alkyl group is unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkyl group is unsubstituted C1-10 alkyl (e.g., -CH3). In some embodiments, the alkyl group is substituted Ci-10 alkyl. Common alkyl abbreviations include -Me (-CH3), -Et (-CH2CH3), -nPr (-CH2CH2CH3), -*Pr (-CH(CH3)2), -nBu (-CH2CH2CH2CH3), -‘Bu (-CH2CH(CH3)2), -sBu (-CH(CH3)(CH2CH3)), and -‘Bu (-C(CH3))3).
[0028] As used herein, the term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carboncarbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds) (“C2-C20 alkenyl”). In some embodiments, alkenyl does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-C10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-C9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-C8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2-C7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-C> alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-C5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-C4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-C3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl”). The one or more carboncarbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (Cs), pentadienyl (Cs), hexenyl (Ce), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cs), octatrienyl (Cs), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkenyl group is unsubstituted C2-10 alkenyl. In some embodiments, the alkenyl group is substituted C2-C10 alkenyl.Page 9 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0029] As used herein, the term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds) (“C2-C20 alkynyl”). In some embodiments, alkynyl does not contain any double bonds. In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-C10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2-C9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-C8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2-C7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2-C6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2-C5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-C4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-C3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carboncarbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2-4 alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-C4 alkynyl groups as well as pentynyl (C5), hexynyl (Ce), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (Cs), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkynyl group is unsubstituted C2-C10 alkynyl. In some embodiments, the alkynyl group is substituted C2-C10 alkynyl.
[0030] The term “haloalkyl” refers to a straight or branched alkyl group that is substituted with one or more halogen atoms.
[0031] As used herein, the term “hydroxyalkyl” refers to refers to alkyl, as defined above, substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6) hydroxy groups. Exemplary hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, and -C CIE OH.
[0032] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent.Page 10 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0033] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent.
[0034] The term “halogen” means -F, -Cl, -Br, or -I.
[0035] The term “heteroatom” refers to oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; and a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).
[0036] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.
[0037] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0038] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of six to fourteen ring members, wherein at least one ring in the system is a 6-carbon atom aromatic ring. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, naphthyl, and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more cycloaliphatic (e.g., cycloalkyl or cycloalkenyl) rings, such as indanyl, tetrahydronaphthyl, and the like. The term “arylenyl” refers to bivalent aryl groups (e.g., phenylenyl). Unless otherwise specified, an aryl is optionally substituted with one or more substituents.
[0039] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable monocyclic or bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, for example an oxygen atom, a sulfur atom or a nitrogen atom. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N-substituted pyrrolidinyl). A heterocyclyl may include one or more bridged bicyclic and / or spirocyclic rings.Page 11 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0040] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 14 ring atoms having 6, 10, or 147t electrons shared in a cyclic array, preferably 5, 6, or 9 ring atoms having 6, 10, or 147t electrons shared in a cyclic array; and wherein in addition to carbon atom(s), at least one ring atom is a heteroatom. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, and phenothiazinyl. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heleroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. The term “heteroarylenyl” refers to bivalent heteroaryl groups (e.g., pyridylenyl).
[0041] Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, oxazepinyl, and morpholinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl or cycloaliphatic rings, such as indolinyl, chromanyl, or tetrahydroquinolinyl. A heterocyclic ring may include one or more oxo (=0) or thioxo (=S) substituent. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
[0042] As described herein, compounds of the disclosure may contain “substituted” moieties. In general, the term “substituted” means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, a substituted group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected fromPage 12 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned in the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0043] Suitable monovalent substituents on a substitutable carbon atom include halogen; -(CH2)O-4R°; -(CH2)O-40R°; -O(CH2)0.4RO, -O-(CH2)0^C(O)ORO; -(CH2)O^CH(OR°)2; -(CH2)O-4SR°: -(CH2)o-4Ph, which may be substituted with R°; -(CH2)o-40(CH2)o iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o-4()(CI I2> i-pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)o^N(R°)2; - (CH2)O-4N(R°)C(0)R°: -N(R°)C(S)R°; -(CH2)0-4N(RO)C(O)NRO2; -N(RO)C(S)NR°2; -(CH2)O-4N(R°)C(0)OR°;N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; -(CII2)o^C(0)R°; -C(S)R°; -(CH2)O^C(0)OR°: -(CH2)( C(O)SR°; -(CH2)0^C(O)OSiR°3; -(CH2)< M0C(0)RO; -OC(0)(CH2)O-4S R°; -(CH2)O-4SC(0)R°; -(CH2)O-4C(0)NR°2; -C(S)NRO2; -C(S)SR°; -SC(S)SR°, -(CH2)O-40C(0)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)o^SSR°; -(CH2)O^S(0)2R°; -(CH2)O ^S(O)2OR°; -(CH2)O-40S(0)2R0; -S(O)2NR°2; -(CH2)O^S(0)R°; -N(RO)S(O)2NR°2; -N(R°)S(O)2R°; -N(OR°)R°; -C(NH)NRO2; -(CH2)( P(O)2R°; -(CH2)O-4P(0)R°2; -(CH2)0^OP(O)RO2; -(CH2)0-4OP(O)(OR°)2; SiR°3; -(Ci-4 straight or branched alkylene)O-N(R°)2; or -(Ci-4 straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, -CH2Ph, -0(CH2)o-iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
[0044] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o-2R*, -(haloR*), -(CH2)O-2OH, -(CH2)0-2OR*, -(CH2)0-2CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)O-2C(0)R*, -(CH2)O-2C(0)OH, -(CH2)O-2C(0)OR*, -(CH2)O-2SR*, -(CH2)O 2SH, - Page 13 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO (CH2)O-2NH2, -(CH2)O-2NHR*, -(CH2)O-2NR*2, -NO2. -SiR*3, -OSiR*3, -C(O)SR* -(Ci-4 straight or branched alkylene)C(O)OR*, or -SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from Ci-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
[0045] Suitable divalent substituents on a saturated carbon atom include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, -O(C(RS'2))2-3O-, or — S(C(R*2))2-3S—, wherein each independent occurrence of R* is selected from hydrogen, Ci-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons include: -O(CR*2)2-3O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0046] Suitable substituents on the aliphatic group of R* include halogen, -R*, -(haloR*), -Oil, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*. -NH2, -NHR*, -NR*2, or -NO2. wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci 4 aliphatic, -CH2PI1, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0047] Suitable substituents on a substitutable nitrogen include -R'. -NR^. -C(O)Rf, -C(O)ORt, -C(O)C(O)Rt, -C(O)CH2C(O)Rt, -S(O)2Rf, -S(O)2NRf2, -C(S)NRf2, -C(NH)NRf2, or -N(Rt)S(O)2Rt; wherein each R' is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0048] Suitable substituents on the aliphatic group of R:are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only withPage 14 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO one or more halogens, and is independently Ci^ aliphatic, -CHzPh, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0049] “Stereoisomers” refers to compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
[0050] “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of n electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound disclosed herein.Other Definitions
[0051] The articles “a” and “an” may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example “an analogue" means one analogue or more than one analogue.
[0052] The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from a subject.
[0053] Disease, disorder, and condition are used interchangeably herein.Page 15 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0054] In general, the “effective amount’’ of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the disclosure may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject.
[0055] As used herein, the term “IRF5 -mediated” disorder, disease, and / or condition means any disorder, disease, or condition in which IRF5 plays a role. In some embodiments, the present disclosure relates to treating or lessening the severity of one or more diseases in which IRF5 plays a role.
[0056] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0057] As used herein, the term “pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
[0058] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds disclosed herein include those derived from suitable inorganic and organic acids and bases. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions. In some embodiments, the provided compounds are purified in salt form for convenience and / or ease of purification, e.g., using anPage 16 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO acidic or basic mobile phase during chromatography. Salts forms of the provided compounds formed during chromatographic purification are contemplated herein (e.g., diammonium salts).
[0059] As used herein, the terms “provided compound” and “disclosed compound” refers to any genus, subgenus, and / or species set forth herein.
[0060] As used herein, the term “reference” describes a standard or control relative to which a comparison is performed. In some embodiments, a “reference” sample or subject is one that is sufficiently similar to a particular sample or subject of interest to permit a relevant comparison. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and / or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and / or comparison to a particular possible reference or control.
[0061] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and / or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal.
[0062] As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (“therapeutic treatment”).Compounds
[0063] Compounds of the present disclosure include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein.Page 17 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Formula A
[0064] Disclosed herein, in some embodiments is a compound of Formula A:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0065] In some embodiments, the compound is of Formula A:or a pharmaceutically acceptable salt thereof, wherein:Page 18 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- Ce alkyl);Z1is -C(O)-, Z2is O, NRZ2, or CR^R24, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or, whereinrepresentsa bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 19 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO2C — &&&. - j &&& each of W1, W, and W3is, independently, CRW, N, or1, wherein >each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, C1-C6 alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e is 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 20 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lxland L2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,C2-C6 alkynylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, L12, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8Page 21 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of L11, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 22 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2-or -C(0)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 memberedPage 23 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2. -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2J-N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached fomr 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0066] In some embodiments, each of W1, W2, and W3is, independently, CRwor N.
[0067] In some embodiments, the compound is of Formula A:Page 24 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula A,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is -C(O)-, Z2is O, NRZ2, or CR^R24, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z3is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each RZ5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or,Page 25 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO,. — j &&wherein * represents a bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, C1-C6 alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-C6 alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OR*, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and C1-C6 haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;eis 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 26 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lxland L2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,C2-C6 alkynylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, L12, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8Page 27 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of L11, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 28 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2-or -C(0)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 memberedPage 29 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2. -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2J-N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached fomr 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0068] It is understood that twoPage 30 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOw iherei •n one && represents a i bond - 1 &&one of * represents a bond to L, as defined in Formula A.Formula I
[0069] Disclosed herein, in some embodiments is a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0070] In some embodiments, the compound is of Formula I:Page 31 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6 alkyl);Z2is NRZ2or CRZ'RZ4:each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 32 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO C — I &&. — && each of V1, V2, V3, and V4is, independently, CRV, N, or <, wherein > representsa bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;1&&&,. - &&& each of W, W2, and W3is, independently, CRW, N, or, wherein *each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-C& haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;Page 33 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-C.6 alkyl and Ci-C.6 haloalkyl;eis 0, 1, 2, 3. 4, 5, or 6;L is selected from the group consisting of:Page 34 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO wherein L comprises at least one 6-membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur that is unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each of Lx1and Lx2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lr1, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 35 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, C1-C6 alkyl, and Ci-Ce haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2- or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 36 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, - SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R. - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene:each RAis, independently, selected from Ci-Cg alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-Cs alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, orPage 37 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0071] In some embodiments, each of W1, W2, and W3is, independently, CRwor N.
[0072] In some embodiments, the compound is of Formula I:or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl):Z2is NRZ2or CRZ'RZ4;each of Z3, Z4, and Z3is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 38 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -0Rza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;_ 00each of V1, V2, V3, and V4is, independently, CRV, N, or *w 1h.erei ■n —s&& represents a i bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3is, independently, CRwor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of -CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(0)Rea, -0Reb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(0)Rya;Page 39 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-C.6 alkyl and Ci-C.6 haloalkyl;eis 0, 1, 2, 3. 4, 5, or 6;L is selected from the group consisting of:Page 40 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO wherein L comprises at least one 6-membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur that is unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each of Lx1and Lx2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lr1, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 41 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, C1-C6 alkyl, and Ci-Ce haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2- or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 42 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, - SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R. - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene:each RAis, independently, selected from Ci-Cg alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-Cs alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, orPage 43 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0073] It is understood that twowherein one o 1 &&represents a bond to L, as defined in Formula I.Formula II
[0074] Disclosed herein, in some embodiments is a compound of Formula II:Page 44 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Formula II,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0075] In some embodiments, the compound is of Formula II:Formula II,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)—, Z2is O, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond:each of Z, Z4, and Z is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each RZ:>is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;Page 45 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;C — &&each of V1, V2, V3, and V4is, independently, CRV, N, orwherei.n J5&& represents a bond teach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;&&&,. - 1 &&& each of W1, W2, and W3is, independently, CRW, N, or, wherein8each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-C6 alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OR* and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selectedPage 46 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO from nitrogen, oxygen, and sulfur, wherein R ' is unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e is 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 47 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lx1and Lx2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from C1-C6alkylene, C2-C6alkenylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5. or 6 RR;each Rxis, independently, selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclicPage 48 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2- or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 49 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-C6 alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, orPage 50 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0076] In some embodiments, each of W1, W2, and W3is, independently, CRwor N.
[0077] In some embodiments, the compound is of Formula II:Formula II,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)~, Z2is O, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 51 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;_ 00each of V1, V2, V3, and V4is, independently, CRV, N, or *each Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R” and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;Page 52 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-C.6 alkyl and Ci-C.6 haloalkyl;eis 0, 1, 2, 3. 4, 5, or 6;L is selected from the group consisting of:Page 53 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each of Lxland *2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,C2-C6 alkynylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;Page 54 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-C.6 haloalkyl;each Rrbis. independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, C1-C6 alkyl, and Ci-Ce haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2- or -C(O)-;X2is N or CH;E1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 55 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2. -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from C i-Cr> alkyl, C2-Ce alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or Page 56 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0078] It is understood that twowherein one ofrepresents a bond tone ofrepresents a bond to L, as defined in Formula II.IRF5 Binding MoietyFormula A
[0079] In some embodiments, the IRF5 binding moiety of the compound of Formula A is a compound of Formula W:Formula W,or a pharmaceutically acceptable salt thereof, wherein:Page 57 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- Ce alkyl);Z1is -C(O)-, Z2is O, NRZ2, or CR^R24, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or&&_ I &&wherein * represents a bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 58 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO C — &&&. - i &&&each of W1, W2, and W3is, independently, CRW, N, ors, wherein > representseach Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and C1-C6 haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of -CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.
[0080] In some embodiments, the IRF5 binding moiety of the compound of Formula A is a compound of Formula W:Page 59 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula W,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is -C(O)-, Z2is O, NRZ2, or CR^R24, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z3is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each RZ5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or,Page 60 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO,. — j &&wherein * represents a bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, C1-C6 alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-C6 alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OR*, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and C1-C6 haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; andeis 0, 1, 2, 3, 4, 5, or 6Formula IPage 61 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0081] In some embodiments, the IRF5 binding moiety of the compound of Formula I is a compound of Formula X:Formula X,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z2is NRZ2or CR^R24;each of Z3, Z4, and Z? is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each RZ:>is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-C.6 alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 62 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of V1, V2, V3, and V4, when not attachedis, independently, CRVor or N;each Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3, when not attached, is, independently,each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;Page 63 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-C.6 alkyl and Ci-C,6 haloalkyl; andeis 0, 1, 2, 3. 4, 5, or 6.
[0082] In some embodiments, the IRF5 binding moiety of the compound of Formula I is a compound of Formula X:Formula X,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z2is NRZ2or CR^R24;each of Z3, Z4, and Z? is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 64 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4, when not attachedis, independently, CRVor or N;each Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-C6 alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;Page 65 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-C.6 alkyl and Ci-C.6 haloalkyl; andeis 0, 1, 2, 3. 4, 5, or 6.Formula II
[0083] In some embodiments, the IRF5 binding moiety of the compound of Formula II is a compound of Formula Y:Formula Y,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)~, Z2is O, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 66 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;_ 00each of V1, V2, V3, and V4is, independently, CRV, N, or *each Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3is, independently, CRW, N, orC &&&,whereineach Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Page 67 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; andeis 0, 1, 2, 3, 4, 5, or 6.
[0084] In some embodiments, the IRF5 binding moiety of the compound of Formula II is a compound of Formula Y:Formula Y,or a pharmaceutically acceptable salt thereof, wherein:Page 68 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- Ce alkyl);Z1is -C(O)-, Z2is O, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or&&_ I &&wherein * represents a bondeach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Page 69 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; andeis 0, 1, 2, 3, 4, 5, or 6.Variables
[0085] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula A, Formula I, and Formula II, and subformulas thereof; or in any one of Formula W, Formula X, and Formula Y, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in somePage 70 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.
[0086] In some embodiments, RZ1is H.
[0087] In some embodiments, RZ1is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci-C6alkyl).
[0088] In some embodiments, RZ1is selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl.
[0089] In some embodiments, RZ1is Ci-Ce alkyl.
[0090] In some embodiments, RZ1is selected from the group consisting of H and Ci-Ce alkyl.
[0091] In some embodiments, RZ1is H, -Me, -Et, -nPr, - Pr, -nBu, -Bu, -sBu, or -‘Bu.
[0092] In some embodiments, RZ1is H, -Me, or -Et.
[0093] In some embodiments, RZ1is H or -Me.
[0094] In some embodiments, Z1is -C(O)-, Z2is O, NRZ2, or CR^R4, and represents a single bond.
[0095] In some embodiments, Z2is O.
[0096] In some embodiments, Z2is NRZ2.
[0097] In some embodiments, Z2is CRZ3RZ4.
[0098] In some embodiments, Z1is -C(O)-, Z2is O, and - - - represents a single bond.
[0099] In some embodiments, Z1is -C(O)-, Z2is NRZ2, and represents a single bond.
[0100] In some embodiments, Z1is -C(O)-, Z2is CRZ3RZ4, and represents a single bond.
[0101] In some embodiments, RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0102] In some embodiments, RZ2is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0103] In some embodiments, RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0104] In some embodiments, RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.
[0105] In some embodiments, RZ2is cyclopropyl, cyclobutyl, or oxetanyl.
[0106] In some embodiments,Page 71 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0107] In some embodiments,
[0108] In some embodiments,
[0109] In some embodiments,
[0110] In some embodiments, Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond.
[0111] In some embodiments, Z1is N, Z2is CRZ3, and represents a double bond.
[0112] In some embodiments, Z1is CRZ3, Z2is CRZ3, and represents a double bond.
[0113] In some embodiments, Z1is N, Z2is N, and represents a double bond.
[0114] In some embodiments, Z1is CRZ3, Z2is N, and represents a double bond.
[0115] In some embodiments, RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0116] In some embodiments, RZ3is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0117] In some embodiments, RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
[0118] In some embodiments, RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.
[0119] In some embodiments, RZ3is cyclopropyl, cyclobutyl, or oxetanyl.
[0120] In some embodiments,
[0121] In some embodiments,
[0122] In some embodiments,
[0123] In some embodiments,
[0124] In some embodiments, R24is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-C6haloalkyl, and -(Ci-C6alkyl)-RY.Page 72 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0125] In some embodiments, RZ4is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-Ce alkyl)-RY.
[0126] In some embodiments, RZ4is selected from the group consisting of H and Ci-Ce alkyl.
[0127] In some embodiments, R74is H, -Me, -Et, -nPr, -‘Pr, -nBu, -’Bu, -sBu, or -‘Bu.
[0128] In some embodiments, R74is H, -Me, or -Et.
[0129] In some embodiments, R24is H or -Me.
[0130] In some embodiments, RZ3and RZ4are taken together with the carbon atom to which each is attached form 3-8 membered monocyclic carbocyclylene.
[0131] In some embodiments, R73and R74are taken together with the carbon atom to which each is attached form 3-6 membered monocyclic carbocyclylene.
[0132] In some embodiments, RZ3and RZ4are taken together with the carbon atom to which each is attached form cyclopropylene or cyclobutylene.
[0133] In some embodiments, Z3is CRZ5.
[0134] In some embodiments, Z4is CR75.
[0135] In some embodiments, Z3is CRZ5.
[0136] In some embodiments, each R75is, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl.
[0137] In some embodiments, each R75is, independently, selected from the group consisting of hydrogen and Ci-Ce alkyl.
[0138] In some embodiments, each R75is, independently, H, -Me, -Et, -nPr, -’Pr, -nBu, -’Bu, -sBu, or -’Bu.
[0139] In some embodiments, each RZ5is, independently, H, -Me, or -Et.
[0140] In some embodiments, each RZ5is, independently, H or -Me.
[0141] In some embodiments, the structurePage 73 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0142] In some embodiments, the structureselected from the group consisting of:
[0143] In some embodiments, the structureselected from the group consisting of:
[0144] In some embodiments, the structureselected from the groupPage 74 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0145] In some embodiments, the structureselected from the group
[0146] In some embodiments, the structureselected from the group consisting of:
[0147] In some embodiments, the structureselected from the groupPage 75 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0148] In some embodiments, the structureselected from the groupC — | &&
[0152] In some embodiments, V2is wherein — I * represents a bond to
[0153] In some embodiments, V2is CRV.&&.. - &&
[0154] In some embodiments, V3is, wherein represents a bond to L.Page 76 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0155] In some embodiments, V4is CRV.
[0156] In some embodiments, each Rvis, independently, selected from the group consisting of hydrogen and Ci-C6 alkyl.
[0157] In some embodiments, each Rvis, independently, H, -Me, -Et, -nPr, -Pr, -nBu, -'Bu, -sBu, or-Bu.
[0158] In some embodiments, each Rvis, independently, H, -Me, or -Et.
[0159] In some embodiments, each Rvis, independently, H or -Me.
[0160] In some embodiments, each Rvis H.
[0161] In some embodiments, W1is CRW.
[0162] In some embodiments, W2is CRW.
[0163] In some embodiments, each Rwis, independently, selected from the group consisting of hydrogen and Ci-C6 alkyl.
[0164] In some embodiments, each Rwis, independently, H, -Me, -Et, -nPr, - Pr, -nBu, - Bu, -sBu, or - Bu.
[0165] In some embodiments, each Rwis, independently, H, -Me, or -Et.
[0166] In some embodiments, each Rwis, independently, H or -Me.
[0167] In some embodiments, each Rwis H.
[0168] In some embodiments, W3is N.
[0169] In some embodiments, each R11is, independently, selected from the group consisting of H and Ci-Ce alkyl.
[0170] In some embodiments, each R11is, independently, H, -Me, -Et, -nPr, - Pr, -nBu, - Bu, -sBu, or -'Bu.
[0171] In some embodiments, each R11is, independently, H, -Me, or-Et.
[0172] In some embodiments, each R11is, independently, H or -Me.
[0173] In some embodiments, each R22is, independently, selected from the group consisting of H and Ci-Ce alkyl.
[0174] In some embodiments, each R22is, independently, H, -Me, -Et, -nPr, - Pr, -nBu, - Bu, -sBu, or - Bu.
[0175] In some embodiments, each R22is, independently, H, -Me, or -Et.
[0176] In some embodiments, each R22is, independently, H or -Me.
[0177] In some embodiments, n is 1, 2, or 3.
[0178] In some embodiments, n is 1 or 2.
[0179] In some embodiments, n is 1.
[0180] In some embodiments, Ring E is phenyl.Page 77 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0181] In some embodiments, Ring E is 3-8 membered monocyclic carbocyclyl.
[0182] In some embodiments, Ring E is 3-6 membered monocyclic carbocyclyl.
[0183] In some embodiments, Ring E is 6 membered monocyclic carbocyclyl.
[0184] In some embodiments, Ring E is cyclohexanyl.
[0185] In some embodiments, Ring E is 5-14 membered bridged bicyclic carbocyclyl.
[0186] In some embodiments, Ring E is 5-10 membered bridged bicyclic carbocyclyl.
[0187] In some embodiments, Ring E is 8-14 membered bridged bicyclic carbocyclyl.
[0188] In some embodiments, Ring E is 5-14 membered spirocyclic carbocyclyl.
[0189] In some embodiments, Ring E is 5-10 membered spirocyclic carbocyclyl.
[0190] In some embodiments, Ring E is 8-14 membered spirocyclic carbocyclyl.
[0191] In some embodiments, each REis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl.
[0192] In some embodiments, each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -'Pr, -nBu, -‘Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
[0193] In some embodiments, each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -'Pr, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
[0194] In some embodiments, e is 0, 1, 2, 3, or 4.
[0195] In some embodiments, e is 2.Page 78 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0198] In some embodiments,selected from the group consisting ofPage 79 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOLinker
[0201] It should be understood that the linkers (L’s) described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular linker (L), that linker (L) can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where linkers are presented as lists, each subgroup of the linkers is also disclosed, and any linker(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all linkers (L’s) described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.
[0202] In some embodiments, L is selected from the group consisting of:Page 80 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lxland I / 2is, independently, -O- or -NRX-;each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene, C2-C > alkynylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, I.1'2. and Lr3is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;Page 81 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rxis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rca, -ORcb, and -N(RCC)2, ortwo Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -C(O)Rra, -ORrb, and -N(Rrc)2, ortwo RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl; andeach Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl.
[0203] In some embodiments, L is selected from the group consisting of:Page 82 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lxland IT2is, independently, -O- or -NRX-;each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene, C2-wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, U2, and Lr3is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;Page 83 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rxis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rca, -ORcb, and -N(RCC)2, ortwo Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -C(O)Rra, -ORrb, and -N(Rrc)2, ortwo RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl; andeach Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl.
[0204] In some embodiments, L comprises at least one 6-membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur that is unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR.
[0205] In some embodiments, L is selected from the group consisting of:Page 84 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOwherein L comprises at least one 6-membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur that is unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each of Lxland L2is, independently, -O- or -NRX-;each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene, C2-wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, L2. and Lr3is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 memberedPage 85 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rca, -ORcb, and -N(RCC)2, ortwo Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -C(O)Rra, -ORrb, and -N(Rrc)2, ortwo RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl; andPage 86 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl.
[0206] In some embodiments, L is selected from the group consisting of:wherein L comprises at least one 6-membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur that is unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each of Lxland L2is, independently, -O- or -NRX-;each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene, C2-Ce alkynylene,Page 87 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, L2, and Lr3is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C’(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rca, -ORcb, and -N(RCC)2, ortwo Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -C(O)Rra, -ORrb, and -N(Rrc)2, ortwo RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 88 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl; andeach Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl.Lcl, Lc2, and Lc3
[0207] In some embodiments, each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene and Ci-C alkynylene,wherein each each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc.
[0208] In some embodiments, each of Lcl, Lc2, and Lc3is Ci-Ce alkylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc.
[0209] In some embodiments, each Rcis, independently, selected from halo, Ci-Ce alkyl, and Ci-C6haloalkyl.
[0210] In some embodiments, each Rcis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -lPr, -nBu, -Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.Lrl, Lr2, and Lr3
[0211] In some embodiments, each of Lrl, E1'2, and Lr3is, independently, selected from 3-8 membered monocyclic carbocyclylene, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR.
[0212] In some embodiments, each of Lrl, L12, and Lr3is, independently, selected from 3-8 membered monocyclic carbocyclylene and 3-8 membered monocyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR.Lxland Lx2Page 89 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0213] In some embodiments, Lxlis -O-. In some embodiments, Lxlis -NRX-
[0214] In some embodiments, Lx2is -O-. In some embodiments, L*2is -NRX- Rx
[0215] In some embodiments, each Rxis, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl. In some embodiments, each Rxis, independently, selected from the group consisting of Ci-Ce alkyl and -C(O)Rxa. In some embodiments, each Rxis, independently, selected from the group consisting of Ci-C6 alkyl. In some embodiments, each Rxis, independently, selected from the group consisting of Ci-Ce haloalkyl. In some embodiments, each Rxis, independently, selected from the group consisting of-C(O)Rxa.Rc
[0216] In some embodiments, each Rcis, independently, selected from the group consisting of halo, Ci-C6alkyl, Ci-C6haloalkyl, -C(O)Rca, -ORcb, and -N(RCC)2.
[0217] In some embodiments, two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.RR
[0218] In some embodiments, each RRis, independently, selected from halo, Ci-Ce alkyl, and Ci-C6haloalkyl.
[0219] In some embodiments, each RRis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, - Pr, -nBu, -Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
[0220] In some embodiments, two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.Rxa
[0221] In some embodiments, each Rxais, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rxais, independently, selected from the group consisting of Ci-Ce haloalkyl.Rea
[0222] In some embodiments, each Rcais, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rcais, independently, selected from the group consisting of Ci-Ce haloalkyl.Rd,Page 90 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0223] In some embodiments, each Rcbis, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rcbis, independently, selected from the group consisting of Ci-Ce haloalkyl.Rcc
[0224] In some embodiments, each Rccis, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rccis, independently, selected from the group consisting of Ci-Ce haloalkyl.Rra
[0225] In some embodiments, each Rrais, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rrais, independently, selected from the group consisting of Ci-C6 haloalkyl.Rrb
[0226] In some embodiments, each Rrbis, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rrbis, independently, selected from the group consisting of Ci-Ce haloalkyl.Rrc
[0227] In some embodiments, each Rrcis, independently, selected from the group consisting of Ci-C6alkyl. In some embodiments, each Rrcis, independently, selected from the group consisting of Ci-Ce haloalkyl.Exemplary Embodiments of L
[0228] In some embodiments, L is selected from the group consisting of:
[0229] In some embodiments, L is selected from the group consisting of:Page 91 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0230] In some embodiments, L is selected from the group consisting of:Page 92 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 93 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 94 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 95 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 96 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 97 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 98 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 99 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 100 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 101 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0234] In some embodiments, L is selected from the group consisting of:
[0235] In some embodiments, L is selected from the group consisting of:Page 102 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO,Page 103 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0238] In some embodiments,
[0239] In some embodiments,Ligase Binding Moiety
[0240] It should be understood that the Ligase Binding Moieties (LBM’s) described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular Ligase Binding Moiety (LBM), that Ligase Binding Moiety (LBM) can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where Ligase Binding Moieties (LBM’s) are presented as lists, each subgroup of the Ligase Binding Moieties (LBM's) is also disclosed, and any Ligase Binding Moiety (LBM) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all Ligase Binding Moieties (LBM’s) described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.
[0241] As described herein, compounds disclosed herein comprise a ligase binding moiety (LBM). The LBM induces ubiquination of IRF5 by an E3 ubiquitin ligase. In some embodiments, the moiety binds to cereblon (CRBN). The moiety which binds to CRBN is referred to herein as a “cereblon binding moiety” or “CBM.” CRBN is a protein that acts as a substrate adapter for the Cullin-4 (CRL4) E3 ubiquitin ligase complex [CRL4CRB], which comprises CRBN, damaged DNA binding protein 1 (DDB1), Cullin-4 A scaffold protein, and regulator of cullins 1 (ROCI). This complex ubiquitinates a number of other proteins and marks them for degradation via the proteasorae.
[0242] In some embodiments, LBM is an E3 ligase ligand. In some embodiments, LBM comprises means for binding an E3 ubiquitin ligase. In some embodiments, LBM comprises means for binding a cereblon E3 ubiquitin ligase.Page 104 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0243] In some embodiments, LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1 or formula I-aa-2:wherein:X1is a bivalent moiety selected from -CH2-or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 105 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo or a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is, independently, selected from RA, halogen, -CN, -NO2, -OR, -SR, -NR2, - SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, and - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from C1-C6 alkyl, C2-Ce alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;Page 106 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0244] In some embodiments, LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1 or formula I-aa-2:I-aa-2,wherein:X1is a bivalent moiety selected from -CEh-or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 107 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo or a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is, independently, selected from RA, halogen, -CN, -NO2, -OR, -SR, -NR2, - SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, and - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from C1-C6 alkyl, C2-Ce alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;Page 108 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0245] In some embodiments, LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:wherein:X1is a bivalent moiety selected from -CFh-or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Page 109 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Ring B is a fused ring selected from benzo or a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is, independently, selected from RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2. -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, and - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0246] In some embodiments, LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:Page 110 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOwherein:X1is a bivalent moiety selected from -CH2-or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring B is a fused ring selected from benzo or a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is, independently, selected from RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - Page 111 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO CR2(NR2), -OC(O)R, -OC(O)NR2. -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, and - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-Cg alkyl, C2-C,6 alkenyl, C2-C,6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
[0247] In some embodiments, L1is absent.
[0248] In some embodiments, L1is -C(O)NR- or -NRC(O)-.Page 112 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0249] In some embodiments, Ring A and its R1substituents is selected from phenylene,
[0250] In some embodiments, Ring B is benzo.
[0251] In some embodiments, Ring B is 5 membered heteroaryl containing 1 -4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0252] In some embodiments, Ring B is 6 membered heteroaryl containing 1 -4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0253] In some embodiments, Ring B is 6 membered heterocyclyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0254] In some embodiments, each R1is, independently, selected from the group consisting of Ci-C6alkyl, halogen, and -OR, ortwo R1groups together with the atom to which each is attached form cyclopropylene or cyclobutylene.
[0255] In some embodiments, LBM is selected from the group consisting of:
[0256] In some embodiments, LBM is selected from the group consisting of:Page 113 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0257] In some embodiments, LBM is selected from the group consisting of:,
[0260] In some embodiments, LBM is selected from the group consisting of:
[0261] In some embodiments, LBM is selected from the group consisting of:[Page 114 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0263] In some embodiments, LBM is selected from the group consisting of:Compounds of the Disclosure
[0265] In some embodiments, the compound is of Formula A-l:Formula A-l,Page 115 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO or a pharmaceutically acceptable salt thereof.
[0266] In some embodiments, the compound is of Formula LA:Formula I- A,or a pharmaceutically acceptable salt thereof.
[0267] In some embodiments, the compound is of any one of Formula I-B to Formula LI:Formula LB, Formula LC,Page 116 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 117 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-H,89 Formula I-I, or a pharmaceutically acceptable salt thereof.
[0268] In some embodiments, the compound is of any one of Formula I-B-l to Formula I- B-6:Page 118 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof.
[0269] In some embodiments, the compound is of any one of Formula I-C-l to Formula I- C-5:Page 119 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 120 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-C-5,or a pharmaceutically acceptable salt thereof.
[0270] In some embodiments, the compound is of any one of Formula I-D-l to Formula I- D-5:Formula I-D-l, Formula I-D-2,Page 121 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-D-5,or a pharmaceutically acceptable salt thereof.
[0271] In some embodiments, the compound is of any one of Formula I-H-l to Formula I- H-4:Page 122 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-H-3, Formula I-H-4, or a pharmaceutically acceptable salt thereof.
[0272] In some embodiments, the compound is of any one of Formula I-G-l to Formula I- G-7:Page 123 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 124 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-G-7,or a pharmaceutically acceptable salt thereof.
[0273] In some embodiments, the compound is of Formula II-A:Page 125 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula II-,or a pharmaceutically acceptable salt thereof.
[0274] In some embodiments, the compound is of any one of Formula II-B to Formula II- J:Page 126 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 127 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula II- J,or a pharmaceutically acceptable salt thereof.
[0275] In some embodiments, the compound is of any one of Formula II-B-1 to Formula II- B-6:Page 128 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 129 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof.
[0276] Disclosed herein, in some embodiments, is a compound of Table 1, or a pharmaceutically acceptable salt thereof.Table 1. Exemplary CompoundsPage 130 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 131 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 132 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0277] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. For example, in some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of formula I as defined above, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound set forth in Table 1 above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound set forth in Table 1 above, together with a pharmaceutically acceptable earner, adjuvant, or vehicle.
[0278] In some embodiments, the present disclosure provides a compound of Formula A, Formula I, or Formula II, or a subformula thereof, as defined above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula A, Formula I, or Formula II, or a subformula thereof, as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle for use as a medicament.
[0279] In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for modulating IRF5 as described herein and / or in a method for treating a IRF5-mediated disorder as described herein. In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for modulating IRF5 as described herein. In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for treating a IRF5-mediated disorder as described herein.
[0280] Disclosed herein, in some embodiments, is a pharmaceutical composition comprising a compound disclosed herein, and a pharmaceutically acceptable excipient thereof.
[0281] Disclosed herein, in some embodiments, is a method of modulating IRF5 in a subject or a biological sample, wherein the method comprises administering to the subject or the biological sample a compound disclosed herein, or a pharmaceutical composition disclosed herein.Page 133 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0282] Disclosed herein, in some embodiments, is a method of treating a IRF5-mediated disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject a compound disclosed herein, or a pharmaceutical composition disclosed herein.
[0283] In some embodiments, the IRF5-mediated disease or disorder is an autoimmune disease.Pharmaceutical Compositions
[0284] Compounds disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) are administered alone or as pharmaceutical compositions comprising the compounds disclosed herein and one or more pharmaceutically acceptable excipients.
[0285] Disclosed herein, in some embodiments, is a pharmaceutical composition comprising a compound disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and a pharmaceutically acceptable excipient (i.e., one or more pharmaceutically acceptable excipients).
[0286] The compounds disclosed herein are used in free base forms, salt forms, or solvate forms, or as prodrugs. All forms are within the compositions (e.g., pharmaceutical compositions) described herein. The disclosed compounds, or salts, solvates, or prodrugs thereof, are administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
[0287] Pharmaceutical compositions described herein are preferably formulated for administration to a subject (e.g., a human) in a biologically compatible form suitable for administration in vivo. Pharmaceutical compositions comprising compounds disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) are useful for treating a disease or disorder, or symptoms thereof, described herein.
[0288] The dosage of the compounds disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) in the pharmaceutical compositions, as well as the amount of the pharmaceutical composition administered to a subject, can vary depending on factors such characteristics of the subject (e.g., age, health, weight, and gender): the nature and extent of the symptoms; the frequency of treatment; the mode of administration of the pharmaceutical compositions; the solubility of the compounds in the pharmaceutical compositions; the potency and activity of the compounds; and the pharmacodynamic properties of the compound. The dosage of the compounds disclosed here (e.g., compounds of Formula Page 134 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) or compositions comprising compounds disclosed herein are varied to achieve a desired therapeutic response for a particular subject, composition, or mode of administration, without being toxic to the subject.
[0289] The present disclosure also provides kits including pharmaceutical compositions comprising compounds disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and package inserts with instructions to perform any of the methods described herein.
[0290] Disclosed herein, in some embodiments, is a process for providing a pharmaceutical composition comprising a compound disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof).Methods of Use and Treatment
[0291] Compounds disclosed herein (e.g., compounds of Formula A, Formula I, and Formula II, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and compositions comprising said compounds as described herein are generally useful for modulating IRF5.
[0292] Disclosed herein, in some embodiments, is a method of degrading IRF5 in a subject, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.
[0293] Also disclosed herein, in some embodiments, is a method of degrading IRF5 in a biological sample, the method comprising contacting said biological sample with a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.
[0294] Also disclosed herein, in some embodiments, is a method of treating an IRF5-mediated disorder, disease, or condition in a subject in need thereof, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.Page 135 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0295] Also disclosed herein, in some embodiments, is a method of degrading IRF5 in a subject, wherein the method comprises administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced IRF5 level relative to the subject prior to administering the compound disclosed herein, or a pharmaceutical acceptable salt thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.
[0296] Also disclosed herein, in some embodiments, is a method of degrading IRF5 in a subject, wherein the method comprises administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced 1RF5 level relative to an untreated subject with the same IRF5 -mediated disorder, disease, or condition. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.
[0297] Also disclosed herein, in some embodiments, is a method of treating a IRF5 -mediated disorder, disease, or condition in a subject in need thereof, wherein the method comprises administering to said subject a compound described herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced 1RF5 level relative to the subject prior to administering the compound described herein, or a pharmaceutical acceptable salt thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.
[0298] Also disclosed herein, in some embodiments, is a method of treating a IRF5 -mediated disorder, disease, or condition in a subject in need thereof, wherein the method comprises administering to said subject a compound described herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced IRF5 level relative to an untreated subject with the same IRF5-mediated disorder, disease, orPage 136 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO condition. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.
[0299] The activity of a compound disclosed herein as a degrader IRF5 may be assayed in vitro, in vivo, or in a cell line. Detailed conditions for assaying a compound disclosed herein as a degrader IRF5 proteins are set forth in the Examples below.
[0300] Compounds disclosed herein are degraders of IRF5 protein and are therefore useful for treating one or more disorders associated with activity of IRF5 protein. Thus, in some embodiments, disclosed herein is a method for treating a IRF5-mediated disorder comprising the step of administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula A, Formula I, or Formula II, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.
[0301] Disclosed herein, in some embodiments, is a method for treating one or more disorders, diseases, and / or conditions wherein the disorder, disease, or condition is an autoimmune disease.
[0302] Diseases and conditions treatable or treated according to the methods disclosed herein include, but are not limited to, ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, vasculitis, inflammatory bowel disease, juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, psoriatic arthritis, sclerosing cholangitis, Sjogren syndrome, cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), systemic scleroderma, Type 1 diabetes mellitus, ulcerative colitis, macrophage activation syndrome (MAS), multiple sclerosis (MS), primary biliary cirrhosis (PBC), myocardial inflammation, and atherosclerosis. In some embodiments, the disease or condition treatable according to the methods disclosed herein is selected from the group consisting of ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, inflammatory bowel disease, juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, sclerosing cholangitis, Sjogren syndrome, systemic lupus erythematosus, systemic scleroderma, Type 1 diabetes mellitus, and ulcerative colitis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is systemic lupus erythematosus (SLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is cutaneous lupus erythematosus (CLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosedPage 137 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO herein is discoid lupus erythematosus (DLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is Sjogren syndrome. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is lupus nephritis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is ulcerative colitis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is rheumatoid arthritis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is systemic scleroderma.EXAMPLES
[0303] The compounds disclosed may be prepared or isolated in general by synthetic and / or semi-synthetic methods known to those skilled in the art for analogous compounds.General Synthetic Methods
[0304] The following examples are intended to be illustrative and are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
[0305] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesize the compounds disclosed herein are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Further, the compounds disclosed herein can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.
[0306] All reactions are carried out under nitrogen or argon unless otherwise stated.
[0307] Proton NMR (1H NMR) is conducted in deuterated solvent. In certain compounds disclosed herein, one or more 'll shifts overlap with residual proteo solvent signals; these signals have not been reported in the experimental provided hereinafter.Page 138 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Table 2. Analytical instruments
[0308] For acidic LCMS data: LCMS was recorded on an Agilent 1200 Series LC / MSD or Shimadzu LCMS2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MH+] and equipped with Chromolith Flash RP-18e 25*2.0 mm, eluting with 0.0375 vol% TFA in water (solvent A) and 0.01875 vol% TFA in acetonitrile (solvent B). Other LCMS was recorded on an Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector. The column used was BEH C18 50*2.1 mm, 1.7 micron. Column flow was 0.55 ml / min and mobile phase were used (A) 2 mM Ammonium Acetate in 0.1 % Formic Acid in Water and (B) 0.1 % Formic Acid in Acetonitrile.
[0309] For basic LCMS data: LCMS was recorded on an Agilent 1200 Series LC / MSD or Shimadzu LCMS 2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MH+] and equipped with Xbridge C18, 2.1X50 mm columns packed with 5 mm C18-coated silica or Kinetex EVO C18 2.1X30mm columns packed with 5 mm CIS-coated silica, eluting with 0.05 vol% NFO-FFO in water (solvent A) and acetonitrile (solvent B).
[0310] HPLC Analytical Method: HPLC was carried out on X Bridge C18 150*4.6 mm, 5 micron. Column flow was 1.0 ml / min and mobile phase were used (A) 0.1 % Ammonia in water and (B) 0.1 % Ammonia in Acetonitrile.
[0311] Prep HPLC Analytical Method: The compound was purified on Shimadzu LC-20AP and UV detector. The column used was X-BRIDGE C18 (250*19)mm, 5p. Column flow was 16.0 ml / min. Mobile phase were used (A) 0.1% Formic Acid in Water and (B) Acetonitrile Basic method used (A) 5mM ammonium bicarbonate and 0.1% NH3 in Water and (B)Page 139 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Acetonitrile or (A) 0.1% Ammonium Hydroxide in Water and (B) Acetonitrile. The UV spectra were recorded at 202nm & 254nm.
[0312] NMR Method: The 1H NMR spectra were recorded on a Bruker Ultra Shield Advance 400 MHz / 5 mm Probe (BBFO). The chemical shifts are reported in part-per-million.
[0313] In some instances, intermediates and compounds described in the examples comprise one or more stereocenters and more than one enantiomer / diastereomer was produced. In some embodiments, these enantiomers / diastereomers were separated and isolated, although stereochemistry was not resolved. Unless otherwise stated, stereochemistry was assigned arbitrarily. For intermediates, each enantiomer / diastereomer with arbitrarily assigned stereochemistry may result in a final compound (e.g., assigned a “I-” number), which also maintains the arbitrarily assigned stereochemistry. Accordingly, any compound with arbitrarily assigned stereochemistry or produced from an intermediate with arbitrarily assigned stereochemistry may be depicted herein as a certain stereoisomer, but it is understood that such compound may be the other stereoisomer (i.e., enantiomer or diastereomer).
[0314] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds disclosed herein, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.Example 1. General SchemesGeneral Scheme 1 - General Synthesis of L and LBM and Linking L-LBM to IRF5 Binding MoietyGeneral Scheme 1Page 140 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0315] Unless specifically defined otherwise within the schemes themselves, all variables in General Scheme 1 are as defined in any one of Formula A, Formula I, and Formula II, and subformulas thereof.
[0316] In General Scheme 1, Reactions A, B, C, and D are indicated with vertical dotted lines and their respective letters in bold, i.e., “A,” “B, “C,” and “D”. Each of these reactions is expanded in their respective boxes within the scheme and is described in the following accompanying text.Reaction A
[0317] Formation of the bond between LAand the 6- membered heteroaryl ring of the IRF5 Binding Moiety was done via palladium-catalyzed Suzuki coupling of a boronic ester or acid on LAwith an aryl halide on the 6-membered heteroaryl, as exemplified in Intermediate 5APage 141 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO synthesis. Alternatively, Sonogashira coupling of an alkyne on LAwas coupled with an aryl halide on the 6-membered heteroaryl to form this C-C bond, as exemplified in Intermediate AV synthesis. Alternatively, a zinc reagent on LAwas used in a palladium catalyzed Negishi coupling reaction with an aryl halide on the 6-membered heteroaryl to form the C-C bond. Furthermore and alternatively, an alkene on LAwas coupled with an aryl halide on the 6-membered heteroaryl with a palladium catalyst. When the bond formed between the 6-membered heteroaryl and LAwas a C-N bond, the amine on the linker LAwas alkylated with an aryl halide on the heteroaryl using a base.Reaction B
[0318] The C-N bond connecting LAto LB, where LBcontains 1 to 3 rings, was formed by the reductive amination of an amine on LBto an aldehyde / ketone on LA. These reactions were performed as described in Example 2. Alternatively, this bond was formed by amide coupling of an amine on LBto a carboxylic acid on LAwith a suitable coupling reagent. The C-N bond connecting LAto LB, where LBis directly attached to Ring A (i.e., Lcis absent), was formed by the alkylation of an amine on LBwith a mesylate on LA, as exemplified in Example 3 Reaction C
[0319] Ring A was attached to LB(z.e., Lcis absent) via the formation of a C-C bond using nickel-iridium catalyzed photochemistry between an aryl halide on Ring A and a bromide on Lc, as exemplified in the Intermediate AL synthesis. Alternatively, an aryl halide on Ring A was cross-coupled with a boronic acid on LBusing various palladium cross-coupling methods. When there is a C-N bond connecting Ring A to LB, an aryl halide on Ring A was coupled with an amine on LBusing various palladium cross-coupling methods, as exemplified in Intermediate 5B synthesis. For compounds where Lcis not absent, the synthesis was carried out by either Reaction A or Reaction B in combination with Reaction D.Reaction D
[0320] Linking Ring A to the glutarimide (GLU) or dihydrouracil (DHU) or a derivative thereof via a direct C-C bond (z'.e., L1is absent) was achieved via a palladium-catalyzed crosscoupling of an aryl halide on Ring A with a boronic acid or ester on the GLU or DHU or a derivative thereof. Alternatively, this bond was formed by alkylation of the aryl halide on ring A with a triflate using a base. Linking Ring A to GLU or DHU or a derivative thereof via a direct C-N bond (L1= 0) was achieved via a copper-catalyzed cross-coupling of an amine on Ring A with a boronic acid or ester on the GLU or DHU or a derivative thereof.
[0321] When L1is not absent, linking Ring A to the glutarimide (GLU) or dihydrouracil (DHU) or a derivative thereof, for example, via an amide linkage was achieved via the condensationPage 142 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO of an amine on the glutarimide (GLU) or dihydrouracil (DHU) and carboxylic acid on Ring A under standard reaction conditions (HATU and a base in a solvent). Linking Ring A to the glutarimide (GLU) or dihydrouracil (DHU) or a derivative thereof, for example, via an ether linkage was achieved via a Williamson ether synthesis of an alcohol on Ring A and bromide on the glutarimide (GLU) or dihydrouracil (DHU) under standard reaction conditions (NaH in a solvent). Furthermore, linking Ring A to the glutarimide (GLU) or dihydrouracil (DHU) or a derivative thereof, for example, via a thiol linkage was achieved via a sulfide formation of a thiol on Ring A and bromide on the glutarimide (GLU) or dihydrouracil (DHU) under standard reaction conditions (K2CO3 in a solvent).Page 143 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO General Scheme 2 - General Synthesis of IRF5 Binding MoietyGeneral Scheme 2
[0322] Unless specifically defined otherwise within the schemes themselves, all variables in General Scheme 2 are as defined in any one of Formula A, Formula I, and Formula II, and subformulas thereof.
[0323] In General Scheme 2, the reactions N-alkylation, palladium-catalyzed coupling, etherification / copper-mediated cross-coupling, and ring formation are indicated with dotted lines. Each of these reactions is expanded within the scheme and is described in the following accompanying text.Etherification or copper-mediated cross-coupling
[0324] The C-0 bond of the ether linkage between the 6-membered heteroaryl and the 9-membered heteroaryl was formed by either etherification or with copper-mediated crosscoupling between a phenol on the 6-membered heteroaryl and an aryl halide on the 9- Page 144 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO membered heteroaryl or alternatively, between a phenol on the 9-membered heteroaryl and an aryl halide on the 6-membered heteroaryl, as exemplified in Intermediate AV and Intermediate 5A syntheses.Palladium-catalyzed coupling
[0325] Synthesizing the C-C bond between the 6-membered heteroaryl and the 5 -membered heteroaryl was achieved using palladium-catalyzed coupling of an aryl (pseudo)halide on the 6-membered heteroaryl with a tributyl tin reagent on the 5-membered heteroaryl via Stille coupling, as described in Intermediate 5A synthesis. Alternatively, this bond was formed via a Suzuki coupling of an aryl (pseudo)halide on the 6-membered heteroaryl with a boronic acid or ester reagent on the 5-membered heteroaryl.N-alkylation
[0326] The C-N bond between the 5-membered heteroaryl and Ring E was accomplished via an N-alkylation between an amine on the 5-membered heteroaryl and a halide or an alcohol on Ring E, as seen in the methodology described for Intermediate D.N-alkylation, Palladium-catalyzed coupling, and ring formation
[0327] Ring Z was alkylated with various groups via an N-alkylation between and amine and a halide on Ring Z, as exemplified in Intermediate AV synthesis. Alternatively, a C-C bond could be formed via Pd-catalyzed coupling of a boronic acid or ester with the halide on Ring Z. Ring formation was subsequently achieved by reacting the amines on Ring Z with an activating agent, such as CDI, as exemplified in Intermediate AV synthesis.Example 3. Synthesis of Intermediatesl-((4,4-Difluorocyclohexyl)methyl)-4-(tributylstannyl)-lH-imidazole (Intermediate D)Step 1 - l,l-difluoro-4-(iodomethyl)cyclohexane
[0328] To a solution of triphenylphosphine (9.61 g, 36.6 mmol) and imidazole (3.85 g, 56.6 mmol) in DCM (50 mL) was added dropwise I2 (9.30 g, 36.6 mmol) at 0 °C. Then the mixture Page 145 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO was stirred at 25 °C for 10 min. Next, (4,4-difluorocyclohexyl)methanol (5 g, 33 mmol, CAS# 178312-48-6) in DCM (20 mL) was added at 0 °C and the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with water (100 mL) and extracted with dichloromethane (3x100 mL). The extracts were washed by brine (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to get the crude residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=l / O to 10 / 1) to give the title compound (8 g, 92% yield). ‘H NMR (400 MHz, DMSO-d6) 5 = 3.28 (d, J = 6.0 Hz, 2H), 2.05 - 1.95 (m, 2H), 1.92 - 1.78 (m, 4H), 1.56 (br s, 1H), 1.31 - 1.21 (m, 2H).Step 2 - l-((4,4-difluorocyclohexyl)methyl)-4-iodo-lH-imidazole
[0329] To a solution of l,l-difhioro-4-(iodomethyl)cyclohexane (8 g, 31 mmol) and 4-iodo-IH-imidazole (2.98 g, 15.3 mmol, CAS# 71759-89-2) in DMF (20 mL) was added CS2CO3 (15.0 g, 46.1 mmol). Then the mixture was stirred at 25 °C for 12 hrs. Upon completion, the reaction mixture was filtered and concentrated in vacuo to give the crude residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 (250*70mm,10 pm);mobile phase: [water(FA)-ACN] gradient: 12%-42% B over 30 min) to give the title compound (1.5 g, 30% yield). ’ll NMR (400 MHz, DMSO-d6) 5 = 8.15 (s, 1H), 7.72 (s, 1H), 7.41 (s, 1H), 3.91 (d, J = 7.2 Hz, 2H), 2.07 - 1.94 (m, 2H), 1.89 - 1.67 (m, 3H), 1.57 (br d, J = 13.4 Hz, 2H), 1.25 - 1.12 (m, 2H).Step 3 - l-((4,4-Difluorocyclohexyl)methyl)-4-(tributylstannyl)-lH-imidazole
[0330] To a solution of l-[(4,4-difluorocyclohexyl)methyl]-4-iodo-imidazole (6 g, 18 mmol) in THF (60 mL) was added dropwise i-PrMgCl (2 M, 18.4 mL) at -10 °C under N2 and the mixture was stirred at -10 °C for 1 h. Next, tributyl(chloro)stannane (7.19 g, 22.0 mmol, 5.94 mL) was added dropwise at -10 °C, then the mixture was stirred at 25 °C for 1 h under N2. Upon completion, the reaction mixture was quenched with aq. NII4CI (20 mL) and extracted with ethyl acetate (3x20 mL). The extracts were washed with brine (20 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude residue. The residue was purified by column chromatography (Al2O3, Petroleum ether / Ethyl acetate=100 / l to 2 / 1) to give the title compound (9 g, 84% yield). LC-MS (ESI+) m / z 491.1(M+H)+.2-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)acetaldehyde (Intermediate AL)Page 146 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOStep 1 - 6-(( l,3-Dioxolan-2-yl)methyl)-3-(2,6-bis(benzyloxy)pyridin-3-yl)-1-methyl- 1 H-indazole
[0331] To a vial equipped with a stir bar was added 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-1 -methyl-indazole (40 g, 79.9 mmol, CAS# 2655649-48-0), 2-(bromomethyl)-l,3-dioxolane (17.3 g, 103 mmol, CAS# 4360-63-8), NiCl2dtbpy (477 mg, 1.20 mmol), TTMSS (23.8 g, 95.9 mmol), 2,6-lutidine (77.0 g, 719 mmol, 83.7 mL) and Ir[dF(CF3)ppy]2(dtbpy)(PF6) (896 mg, 799 pmol) in DME (800 mL). The vial was sealed and placed under nitrogen and the reaction was stirred and irradiated with a 400 W [395 nm] blue LED lamp (3 cm away), with cooling water to keep the reaction temperature at 25 °C for 8 hrs. Upon completion, the mixture was concentrated in vacuo. Then the crude product was diluted with water (300 mL) and extracted with EA (400 mL X 2). The combined organic layers were washed with brine (100 mL X 5), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (S1O2, PE: EA=10:l to 2:1 ). Then, the crude product was triturated with PE: EA=3: 1 (80 mL) at 25 °C for 5 min, and filtered and dried to give the title compound (21.8 g, 53% yield).1H NMR (400 MHz, DMSO-d6) δ 7.90 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.53 - 7.43 (m, 3H), 7.42 - 7.26 (m, 8H), 6.96 (d. J = 8.4 Hz, 1H). 6.58 (d, J = 8.0 Hz, 1H), 5.44 (d, J = 16.4 Hz, 4H), 5.04 (t, J = 4.8 Hz, 1H), 4.10 - 4.00 (m, 3H), 3.89 (t, J = 6.8 Hz, 2H), 3.82 - 3.73 (m, 2H), 3.01 (d, J = 4.4 Hz, 2H).Step 2 - 3-(6-((l,3-Dioxolan-2-yl)methyl)-l-methyl-lH-indazol-3-yl)piperidine-2,6-dionePage 147 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0332] To a solution of 3-(2,6-dibenzyloxy-3-pyridyl)-6-(L3-dioxolan-2-ylmethyl)-l-methyl-indazole (21.8 g, 42.95 mmol) in THF (400 mL) was added Pd / C (10 g, 10 wt%) under N2. The suspension was degassed under vacuum and purged with H2 several times, then the mixture was stirred under H2 (30 psi) at 30 °C for 4 hrs. Upon completion, the mixture was filtered and the filtrate was concentrated in vacuo to give the title compound (14.1 g, 99% yield).1H NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 7.61 (d, J = 8.4 Hz. 1H), 7.45 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 5.04 (t, J = 4.8 Hz, 1H), 4.34 (dd, J = 5.2, 9.6 Hz, 1H), 4.02 - 3.94 (m, 3H), 3.93 -3.84 (m, 2H), 3.82 - 3.70 (m, 2H), 3.02 (d, J= 4.8 Hz, 2H), 2.73 - 2.56 (m, 2H), 2.34 (tdd, 7 = 4.8, 9.2, 14.0 Hz. 1H), 2.22 - 2.12 (m, 1H)Step 3 - 2-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)acetaldehyde
[0333] A mixture of 3-[6-(l,3-dioxolan-2-ylmethyl)-l-methyl-indazol-3-yl]piperidine-2,6-dione (240 mg, 728 pmol) in HCOOH (1 mL) was stirred at 60 °C for 2.5 hrs. Upon completion, the mixture was concentrated in vacuo to give the title compound (207 mg, 99% yield). LC-MS (ESU) m / z 304.0 (M+H+18)+.Tert-butyl 4-(4-(2-chloro-6-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol- 4-yl)oxy)pyridin-4-yl)but-3-yn-l-yl)piperazine-l-carboxylate (Intermediate AV)Step 1 - 3-(Benzyloxy)-N-cyclopropyl-2-nitroaniline
[0334] To a mixture of cyclopropanamine (17.3 g, 303 mmol, 21.0 mL, CAS# 765-30-0), 1-(benzyloxy)-3-fhioro-2-nitrobenzene (15 g, 61 mmol, CAS# 920284-79-3) in NMP (120 mL) was added K2CO3 (16.7 g, 121 mmol). The reaction mixture was degass and charged with N2Page 148 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO for three times and then heated to 80 °C for 14 h. Upon completion, the reaction mixture was quenched with H2O (300 mL) and then extracted with EtOAc (200 mL x 2). The organic layer was dried over Na2SO4and then concentrated under vacuum to get the residue. The residue was purified by flash silica gel chromatography (0-6% ethyl acetate in petroleum ether) to give the title compound (16.4 g, 95% yield). LC-MS (ESI+) m / z 285.1 (M+H)+.Step 2 - 3-(Benzyloxy)-N 1 -cyclopropylbenzene-1,2-diamine
[0335] To a solution of 3-(benzyloxy)-N-cyclopropyl-2-nitroaniline (16.2 g, 56.9 mmol) in H2O (60 mL) and EtOH (120 mL) was added NH4CI (21.3 g, 398 mmol). Then Fe (15.9 g, 284 mmol) was added into the solution in batches. The mixture was then stirred at 80 °C for 2 h. Upon completion, the reaction mixture was filtered to give a filtrate, which was washed with water (100 mL) and the mixture was extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (300 mL) and then dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the compound (14.2 g, 85% yield). LC-MS (ESI+) m / z 255.1 (M+H)+.Step 3 - 4-(Benzyloxy)-l-cyclopropyl-lH-benzo[d]imidazol-2(3H)-one
[0336] To a solution of 3-benzyloxy-Nl-cyclopropyl-benzene-l,2-diamine (13 g, 51.1 mmol) and di(imidazol-l-yl)methanone (12.4 g, 76.6 mmol) in DMF (130 mL) was added DIEA (19.8 g, 153 mmol, 26.7 mL) under nitrogen flow. Then the reaction was stirred at 100 °C for 12 h under nitrogen atmosphere. Upon completion, the mixture was dropped into water (500 mL) under agitation. During this period white precipitate was formed, which was washed with water (100 mL) and collected by filtration and dried to afford the compound (12.7 g, 89% yield). LC-MS (ESI+) m / z 281.2 (M+H)+.Step 4 - l-Cyclopropyl-4-hydroxy-lH-benzo[d]imidazol-2(3H)-one
[0337] 4-(Benzyloxy)-l-cyclopropyl-lH-benzo[d]imidazol-2(3H)-one (13.4 g, 47.9 mmol) was added to a three-necked bottle, which was degassed and purged with N2 three times. Then BBrg (2 M, 50 mL) was added dropwise at 20 °C and the mixture was stirred at 20 °C for 12 h under N2. Upon completion, the reaction mixture was quenched with MeOH (50 mL) at 0 °C and concentrated under reduced pressure to give a residue. The crude product was triturated with MeOH: DCM=10 / l (10 ml) at 50 °C for 30 min filtered to afford the compound (10.6 g). LC-MS (ESI+) m / z 191.0 (M+H)+.Step 5 - 4-((6-Chloro-4-iodopyridin-2-yl)oxy)-l-cyclopropyl-lH-benzo[d]imidazol-2(3H)-onePage 149 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0338] To a solution of l-cyclopropyl-4-hydroxy-lH-benzo[d]imidazol-2(3H)-one (4 g, 21 mmol), 2,6-dichloro-4-iodo-pyridine (4.80 g, 17.5 mmol, CAS# 98027-84-0) in NMP (50 mL) was added K2CO3 (7.27 g, 52.5 mmol). Then the mixture was stirred at 130 °C for 6 h. Upon completion, the reaction mixture was purified directly without work up. The residue was purified by reversed phase column (C 18, mobile phase: [water (0.1% FA)-ACN]; B%: 45%-65%, 25 min) and the solvent was removed by rotary evaporation to afford the compound (1.4 g, 16% yield). LC-MS (ESI+) m / z 427.9 (M+H)+.Step 6 - Tert-butyl 4-(4-(2-chloro-6-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)pyridin-4-yl)but-3-yn-l-yl)piperazine-l -carboxylate
[0339] To a solution of 4-((6-chloro-4-iodopyridin-2-yl)oxy)-l -cyclopropyl- 1H-benzo[d]imidazol-2(3H)-one (800 mg, 1.87 mmol), tert-butyl 4-but-3-ynylpiperazine-l-carboxylate (445 mg, 1.87 mmol, CAS# 1232152-74-7) in DMF (10 mL) was added Pd(PPh3)4 (216 mg, 187 pmol), Cui (178 mg, 935 pmol), and DIEA (483 mg, 3.74 mmol). The mixture was then stirred at 60 °C for 3 h. Upon completion, the mixture was concentrated under vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 20 g SepaFlash Silica Flash Column, Eluent of 0-70% Ethyl acetate / Petroleum ether gradient @ 100 niL / min) to afford the compound (700 mg, 68% yield). LC-MS (ESI+) m / z 538.5 (M+H)+.l-Cyclopropyl-4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yl)-4-(4- (piperazin-1-yl)but-l-yn-l-yl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one (Intermediate AW)Page 150 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Step 1 - Tert-butyl4-(4-(2-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l-((4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yl)pyridin-4-yl)but-3-yn-l-yl )piperazme-l -carboxylate
[0340] A mixture of tert-butyl 4-(4-(2-chloro-6-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d] imidazol-4-yl)oxy)pyridin-4-yl)but-3-yn-l-yl)piperazine-l -carboxy late (300 mg, 557 prnol. Intermediate AV), l-((4,4-difluorocyclohexyl)methyl)-4-(tributylstannyl)-lH-imidazole (818 mg, 1.67 mmol, Intermediate D), and Pd(t-BusP)2 (113 mg, 223 prnol) in DMF (8 mb) was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C for 2 h under N2. Upon completion, the mixture was diluted with EA (20 mL) and water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (20 mL) and then dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0 4% MeOH / DCM gradient @ 40 mL / min) to afford the compound (170 mg, 39% yield). LC-MS (ESI+) m / z 702.4 (M+H)+.Step 2 - l-Cyclopropyl-4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yl)-4-(4-(piperazm-l-yl)but-l-yn-l-yl)pyridm-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one
[0341] To a solution of tert-butyl leit-butyl 4-(4-(2-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l-((4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yl)pyridin-4-yl)but-3-yn-l-yl)piperazine-l -carboxylate (150 mg, 213 prnol) in DCM (2 ml.) was added TFA (1.35 g, 11.8 mmol, 882 pL). The mixture was then stirred at 20 °C for 1 h. Upon completion, the mixture was concentrated under vacuum to afford the title compound (250 mg, 98% yield, TFA). LC-MS (ESU) nt / z 602.3 (M+H)+.3-(l-Methyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine- 2, 6-dione (Intermediate AC) (Intermediate 5B)Page 151 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOStep 1 - Tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l -methyl-1 H-indazol-6-yl)piperazine-l- carboxylate
[0342] To a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole (500 mg, 999 pmol, CAS# 2655649-48-0) and tert-butyl piperazine- 1 -carboxylate (372 mg, 2.00 mmol, CAS# 57260-71-6) in toluene (5 mL) was added CS2CO3 (978 mg, 3.00 mmol) and RuPhos Pd G3 (83.57 mg, 99.9 pmol). The mixture was then stirred at 100 °C for 12 h under N2. Upon completion, the reaction mixture was quenched with water (15 mL) at 20 °C, and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=l / O to 3 / 1) to afford the title compound (366 mg, 61% yield). LC-MS (ESI+) m / z 606.7 (M+1H); ’ll NMR (400 MHz, DMSO-d6) 5 = 7.89 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.49 -7.43 (m, 2H), 7.42 - 7.33 (m, 5H), 7.32 - 7.25 (m, 3H), 6.89 (s, 1H), 6.83 (br d, J= 9.2 Hz, 1H), 6.56 (d, J= 8.0 Hz, 1H), 5.43 (br d, J = 14.4 Hz, 4H), 3.97 (s, 3H), 3.49 (br s, 4H), 3.18 (br d, 7 = 4.4 Hz, 4H), 1.43 (s, 9H).Step 2 - Tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-mdazol-6-yl )piperazine-l -carboxylate
[0343] To a solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)piperazine- 1 -carboxylate (360 mg, 594 pmol) in THF (5 mL) was added Pd / C (150 mg,Page 152 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 141 prnol. 10 wt%). The mixture was then stirred at 40 °C for 12 h under H2. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to afford the title compound (200 mg, 79% yield). LC-MS (ESI+) m / z 428.2 (M+l H)+.Step 3 - 3-(l-Methyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione
[0344] A solution of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperazine- 1 -carboxylate (200 mg, 468 (imol) in HCl / dioxane (2 M, 4 mL) was stirred at 20 °C for 1 h. Upon completion, the reaction mixture was concentrated under reduced pressure to afford the title compound (200 mg, 100% yield, HC1). LC-MS (ESI+) m / z 328.2 (M+1H)+.l-(l-(4,4-DifluorocyclohexyI)ethyl)-4-(tributylstannyl)-lH-imidazole (Intermediate AR)Step 1 - 4,4-Difluoro-N-methoxy-N-methylcyclohexanecarboxcunide
[0345] To a solution of N, O-dimethylhydroxylamine hydrochloride (163 g. 1.68 mol, CAS# 6638-79-5), HATU (637 g, 1.68 mol) and DIEA (394 g, 3.05 mol) were added in a solution of 4,4-difluorocyclohexanecarboxylic acid (250 g, 1.52 mol, CAS# 122665-97-8) in DMF (2 L) at 20 °C, and the mixture was stirred for 1 h. Upon completion, the reaction mixture was poured into water (4000 mL), and then extracted with EtOAc (1000 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO: 5000 g SepaFlash Silica Flash Column, Eluent of 0-30% Ethyl acetate / Petroleum ethergradient @ 400 mL / min) to give the title compound (680 g, 97% yield).Step 2 - l-(4,4-Difluorocyclohexyl)ethanone
[0346] A mixture of 4,4-difluoro-N-methoxy-N-methylcyclohexanecarboxamide (220 g, 956 mmol) in THE (2 L) was added bromo(methyl)magnesium (3 M, 414 mL) at 0 °C under N2, and the mixture was stirred at 25 °C for 2 h. Upon completion, the reaction mixture was pouredPage 153 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO into water (2000 mL), and then extracted with EtOAc (1000 mL x 3). The combined organic layers were washed with brine (1000 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 4000 g SepaFlash Silica Flash Column, Eluent of 0-30% Ethyl acetate / Petroleum ether gradient @ 400 niL / min) to give the title compound (258 g, 83% yield).Step 3 - l-(4,4-Difluorocyclohexyl)ethanol
[0347] A mixture of l-(4,4-difluorocyclohexyl)ethanone (258 g, 1.59 mol) in EtOH (2.5 L) was added NaBEU (77.1 g, 2.04 mol) at 0 °C under N2. The mixture was stirred at 0 °C for 1 h. Upon completion, the reaction mixture was poured into NH4CI solution (1000 mL), and then extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SOr, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=20 / l-3 / l) to give the title compound (208 g, 80% yield), ’ll NMR (400 MHz, CDCb-d) 5 = 3.64 (quin, J = 5.6 Hz, 1H), 2.18 - 2.06 (m, 2H), 2.02 - 1.90 (m, 1H), 1.80 - 1.59 (m, 3H), 1.42 - 1.32 (m, 3H), 1.20 (dd, J = 1.2, 6.4 Hz, 3H).Step 4 - l-(l-(4,4-Difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole
[0348] A mixture of 4-iodo-lH-imidazole (11.8 g, 60.9 mmol, CAS# 71759-89-2), l-(4,4-difluorocyclohexyl)ethanol (10 g, 60.9 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (14.7 g, 60.9 mmol) in toluene (100 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C for 12 h under N2. Upon completion, the reaction mixture was poured into water (200 mL), and then extracted with EtOAc (300 mL x 3). The combined organic layers were washed with brine (300 mL x 3), dried over Na2SOa, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, Petroleum ether / Ethyl acetate=20 / l-3 / l). Then the residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm,10 pm); mobile phase:[water(FA)-ACN];gradient:20%-50% B over 20 min ) to give desired compound. Next, the residue was purified by flash silica gel chromatography (SiO2, Petroleum ether / Ethyl acetate=3 / l) to give the title compound (3.5 g, 17% yield). LC-MS (ESI+) m z 340.9 (M+H)+; ’ll NMR (400 MHz, DMSO-d6) 5 =7.70 (s, 1H), 7.46 (s, 1H), 4.18 - 4.07 (m, 1H), 2.06 - 1.91 (m, 3H), 1.86 - 1.66 (m, 4H), 1.40 (d, J= 6.8 Hz, 3H), 1.22 - 1.15 (m, 2H).Step 5 - l-(l-(4,4-Difluorocyclohexyl)ethyl)-4-(tributylstannyl)-lH-imidazole
[0349] To a solution of l-(l-(4,4-difhiorocyclohexyl)ethyl)-4-iodo-lH-imidazole (7.5 g, 22.0 mmol) in THF (20 mL) was added chloro(isopropyl)magnesium (2 M, 22.1 mL) and the Page 154 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO mixture was degassed and purged with N2 three times. Then the mixture was stirred at 0 °C for 1 h under N2. Next, tributyl(chloro)stannane (8.61 g, 26.5 mmol, 7.12 mL) was added and the mixture was stirred at 0 °C under N2 for 1 h. Upon completion, the reaction mixture was quenched with aq. NH4C1 (20 mL) and extracted with EtOAc (3x20 mL). The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (16.3 g). LC-MS (ESI+) m / z 505.1 (M+H)+.(S)- 1-( l-(4,4-difluorocyclohexyl)ethyl)-4-(tributylstannyl)- 1 / / -imidazole (Intermediate AN)Step 1 - (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole
[0350] l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (synthesized via Steps 1-4 of Intermediate AR, 35 g) was purified by SEC (column: DA1CEL CHIRALPAK 1C (250mm*50mm,10 pm);mobile phase: [CO2-MeOH(0.1%NH3H2O)];gradient:30%-% B over 3.5 min) to afford the first eluting peak as (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (17.1 g, 46% yield).Step 2 - (S)- 1 -( I -(4,4-difluorocyclohexyl)ethyl)-4-(tributylstannyl)- 1 H-imidazole
[0351] To a solution of (S)-l-(L(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (24.5 g, 72.0 mmol) in THF (200 mL) was added chloro(isopropyl)magnesium (2 M, 72.03 mL) and the mixture was degassed and purged with N2 three times. Then the mixture was stirred at 0 °C for 2 h under N2. Next, tributyl(chloro)stannane (28.1 g, 86.4 mmol, 23.3 mL) was added and the mixture was stirred at 0 °C under N2 for 2 h. Upon completion, the reaction mixture was quenched with aq. NH4C1 (20 mL) and extracted with EtOAc (3x20 mL). The extracts were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (34.5 g). LC-MS (ES1+) m / z 505.1 (M+H)+.l-Cyclopropyl-4-hydroxy-3-((2-(trimethylsiIyI)ethoxy)methyI)-lH-benzo[d]imidazol-2(3H)-one (Intermediate QA)Page 155 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOStep 1 - 4-(benzyloxy)-l-cyclopropyl-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[ d ]imidazol-2( 3H)-one
[0352] To a solution of 7-benzyloxy-3-cyclopropyl-7H-benzimidazol-2-one (8.35 g, 29.8 mmol, synthesized via Steps 1-3 of Intermediate AV) in THF (85 mL) was added LiHMDS (1 M, 44.68 mL) at 0 °C and the mixture was stirred 1 h. Next, SEM-C1 (9.93 g, 59.6 mmol, 10.5 mL) was added and the mixture was stirred at 25 °C for 12 h. The mixture was quenched with NH4CI (100 mL) at 0 °C, and diluted with EA (100 mL). The aqueous phase was extracted with EA (100 mL x 3). The combined organic phase was washed with brine (300 mL), dried with anhydrous NazSCL. filtered and concentrated in vacuo to give residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash Silica Flash Column, EA / PE: 0-50%) to afford the title compound (11.5 g, 94% yield).Step 2 - l-cyclopropyl-4-hydroxy-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[dJimidazol-2(3H)-one
[0353] To a solution of 4-benzyloxy-l-cyclopropyl-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (11.5 g, 28.0 mmol) in MeOH (120 mb) was added Pd / C (3.83 g, 3.60 mmol, 10 wt%) under N2 atmosphere. The suspension was degassed and purged with H2 3 times, then the mixture was stirred under H2 (15 Psi.) at rt for 12 h. The mixture was filtered and the filtrate concentrated under reduced pressure to give the title compound (7.75 g, 86% yield).((lS,4R)-4-((2-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l-((S)-l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)pyridin-4-yl)inethyl)cyclohexyl)methyl methanesulfonate (Intermediate 5A)Page 156 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOStep 1 - (lr,4r)-Ethyl 4-( 2,6-dichloropyridin-4-yl)methyl)cyclohexanecarboxylate
[0354] To a solution of ethyl 4-methylenecyclohexanecarboxylate (10 g, 60 mmol, CAS# 145576-28-9) in THF ( 1 mL) was added 9-BBN (0.50 M, 142 mL), then the mixture was stirred at 80 °C for 2 h. Next, the mixture was cooled to 25 °C and 2,6-dichloro-4-iodopyridine (16.2 g, 59.4 mmol, CAS# 98027-84-0), Pd(dppf)Cl2(4.35 g, 5.94 mmol), K2CO3(9.86 g, 71.3 mmol), DMF (100 mL) and H2O (10 mL) were added to the mixture and the mixture was degassed and purged with N2 three times. Then the mixture was stirred at 80 °C for 12 h under N2. Upon completion, the mixture was quenched with H2O ( 100 mL) at 25 °C, and then dilutedPage 157 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO with ethyl acetate (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with NaCl (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=99 / l to 98 / 2) to give the title compound (7.35 g, 30% yield). LC-MS (ESI+) m / z 316.0 (M+H)+.Step 2 - (lR,4R)-ethyl 4-((2-chloro-6-((l-cyclopropyl-2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro- 1 H-benzo[d]imidazol-4-yl)oxy)pyridin-4-yl)methyl)cyclohexanecarboxylate
[0355] A mixture of (l / ?,4 / ?)-ethyl 4-((2,6-dichloropyridin-4-yl)methyl)cyclohexanecarboxylate (3.55 g, 11.2 mmol), l-cyclopropyl-4-hydroxy-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (3.00 g, 9.36 mmol, Intermediate QA), CU2O (268 mg, 1.87 mmol), MNBO (298 mg, 936 pmol) and K3PO4 (2.58 g, 12.2 mmol) in DMSO (40 mL) was degassed and purged with N23 times. Then the mixture was stirred at 100 °C for 12 h under N2 atmosphere. The mixture was extracted with EtOAc (300 mL). The combined organic extracts were washed with saturated brine (90 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by column chromatography (PE / EtOAc = 50 / 1 to 15 / 1) to give the title compound (3.50 g, 62% yield). LC-MS (ESI+) m / z 622.3(M+Na)+.Step 3 - (lR,4R)-ethyl 4-((2-chloro-6-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)pyridin-4-yl)melhyl)cyclohexanecarboxylate
[0356] To a solution of ( 1 / 4 / )-ethyl 4-((2-chloro-6-((l-cyclopropyL2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)pyridin-4-yl)methyl)cyclohexanecarboxylate (3.30 g, 5.50 mmol) in DCM (5 mL) was added TFA (135 mmol, 10 mL), and the mixture was stirred at it for 0.5 h. The mixture was quenched with Nal ICO (50 mL), and extracted with DCM (200 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Then the residue was dissolved in NII? / McOII (10 mL) and stirred at rt for 1 h. The mixture was concentrated under vacuum to remove solvent. The crude product was triturated with EtOAc to give the title compound (2.10 g, 81% yield). LC-MS (ESC) m / z 470.2 (M+H)+.Step 4 - 4-((6-Chloro-4-(((lR,4R)-4-(hydroxymethyl)cyclohexyl)methyl)pyridin-2-yl )oxy)-l -cyclopropyl-1 H-benz,o[d ]imidazol-2( 3H)-one
[0357] To a solution of (l / ?,4 / ?)-ethyl 4-((2-chloro-6-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)pyridin-4-yl)methyl)cyclohexanecarboxylate (2.10 g, 4.47 mmol)Page 158 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO in THF (50 mL) was added dropwise LAH (2.5 M, 2.68 mL) at 0 °C under N2 atmosphere. The mixture was stirred at 0 °C for 2 h under N2 atmosphere. The mixture was quenched with H2O (0.254 mL) and NaOH (0.254 mL, 15% solution), and more H2O (0.762 mL). Then the mixture was filtered and concentrated under reduced pressure to give the title compound (2.00 g, 94% yield). LC-MS (ESI+) m / z 428.1 (M+H)+.Step 5 - l-cyclopropyl-4-((6- l-( S)-l- 4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-(( lR,4S)-4-(hydroxymethyl)cyclohexyl)methyl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one
[0358] A mixture of 4-((6-chloro-4-(((l / ?,4 / ?)-4-(hydroxymethyl)cyclohexyl)methyl)pyridin-2-yl)oxy)-l-cyclopropyl-lH-benzo[d]imidazol-2(3H)-one (600 mg, 1.40 mmol), tributyl-[l-[(1S)-1 -(4, 4-difhiorocyclohexyl)ethyl]imidazol-4-yl] stannane (1.41 g, 2.80 mmol, Intermediate AN), and Pd(t-Bu3P)2 (287 mg, 561 pmol) in DMF (5 mL) was degassed and purged with N2 3 times. Then the mixture was stirred at 100 °C for 2 h under N2 atmosphere. The mixture was extracted with EtOAc (150 mL). The combined organic extracts were washed with saturated brine (60 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (DCM / MeOH = 10 / 1) to give compound (500 mg, 825 prnol, 59% yield). LC-MS (ESI+) m / z 606.3 (M+H)+.Step 6 - ((lS,4R)-4-((2-((l-cyclopropyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l- (S)-l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)pyridin-4-yl)melhyl)cyclohexyl)melhyl melhanesulfonale
[0359] To a solution of Lcyclopropyl-4-((6-(L((S)-L(4,4-difhiorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-(((l / ?,4S)-4-(hydroxymethyl)cyclohexyl)methyl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one (300 mg, 495 pmol) in DCM (10 mL) was added TEA (150 mg, 1.49 mmol) and methylsulfonyl methanesulfonate (173 mg, 991 pmol). The mixture was stirred at rt for 0.5 h. The mixture was concentrated under vacuum to remove solvent. The residue was purified by column chromatography (DCM I MeOH=l / 0 to 40 / 1) to give compound (260 mg, 380 pmol, 77% yield). LC-MS (ESF) m / z 684.2 (M+H)+.Example 4. Method 1: Synthesis of Compound 1-1Page 159 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO
[0360] To a solution of Intermediate AL and Intermediate AW in THF and DMSO was added NaBH(0Ac)3 and HOAc. The mixture was then stirred at 25 °C for 2 h. Upon completion, the reaction mixture was filtered. The residue was purified by prep-HPUC (column: Xtimate C18 150*40mm*10 pm;mobile phase: [water(FA)-ACN];gradient:5%-35% B over 10 min) to afford the title compound. LC-MS (ESI+) m / z 871.6 (M+H)+. ’ll NMR (400 MHz, DMSO-d6) 5 = 10.99 - 10.90 (m, 1H), 10.87 (s, 1H), 7.69 (d, J = 1.2 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.48 (d, 7 = 1.2 Hz, 1H), 7.42 (s, 1H), 7.34 (d, J = 1.2 Hz, 1H), 7.08 - 7.02 (m, 2H), 7.02 - 6.98 (m, 1H), 6.83 (dd, J = 2.4, 6.8 Hz, 1H), 6.55 (d, J = 1.2 Hz, 1H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 3.95 (s, 3H), 3.91 (br d, J = 7.2 Hz, 2H), 2.87 (dt, J = 3.6, 6.8 Hz, 3H), 2.69 - 2.55 (m, 10H), 2.47 - 2.44 (m, 4H), 2.41 - 2.26 (m, 3H), 2.21 - 2.13 (m, 1H), 2.04 - 1.94 (m, 2H), 1.85 - 1.68 (m, 3H), 1.56 (brd, J= 12.4 Hz, 2H), 1.24 - 1.13 (m, 2H), 1.05 - 0.98 (m, 2H), 0.93 - 0.86 (m, 2H).Table 3. Compounds synthesized via Method 1, the reductive amination of amines andcarbonylsPage 160 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOaThe reductive amination was run under standard conditions with amines and aldehydes or ketones from 0-60 °C for 1-12 hr. NaBH₃CN could be used as reducing agent; TEA added to adjust pH to basic when need; 4 A molecular sieves could also be added to promote the reductive amination. The compounds were purified under a variety of standard techniques.For compounds noted with a footnote about further separation into diastereomers, the absolute configuration was arbitrarily assigned.Example 5. Method 4: Synthesis of Compound 1-5
[0361] To a solution of Intermediate 5A in DMF was added DIEA and Intermediate 5B and KI. The mixture was then stirred at 100 °C for 12 hr. Upon completion, the mixture was extracted with EtOAc. The combined organic extracts were washed with saturated brine, dried Page 161 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO over Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (neutral condition) to give the title compound. LC-MS (ESI+) m / z. 915.5 (M+H)+;!H NMR (400 MHz, DMSO-^e) 6= 11.06 - 10.53 (m, 1H), 7.73 (s, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.45 -7.40 (m, 1H), 7.32 (s, 1H), 7.07 - 6.99 (m, 2H), 6.95 - 6.87 (m, 1H), 6.82 (s, 1H), 6.80 - 6.74 (m, 1H), 6.49 (s, 1H), 4.30 - 4.20 (m, 1H), 4.20 - 4.08 (m, 1H), 3.88 (s, 3H), 3.35 - 3.33 (m, 3H), 3.20 (s, 4H), 2.92 - 2.84 (m, 1H), 2.65 - 2.55 (m, 4H), 2.31 - 2.20 (m, 1H), 2.19 - 2.09 (m, 3H), 2.08 - 1.99 (m, 1H), 1.99 - 1.90 (m, 1H), 1.88 - 1.76 (m, 4H), 1.76 - 1.73 (m, 1H), 1.73 -1.60 (m, 4H), 1.56 - 1.45 (m, 2H), 1.44 - 1.37 (m, 3H), 1.31 - 1.20 (m, 2H), 1.19 - 1.09 (m, 1H), 1.08 - 1.01 (m, 3H), 1.01 - 0.92 (m, 2H), 0.92 - 0.88 (m, 2H), 0.88 - 0.76 (m, 2H).Table 4“The nucleophilic substitution of mesylates with amines was run under standard coupling conditions at 80-100 °C for 1-12 hr. The purification of the final compounds was performed under standard techniques.Example 6. IRF5 HiBiT Degradation
[0362] HiBiT assay was conducted with THPl-IRF5-HiBiT clonal cells. 1,500 cells / well were treated with compounds in 384 well plate at various concentrations starting from 1 pM and incubated for 24 hr at 37 °C in 5% CO2. On the second day, cells in plates were equilibrated to RT (room temperature), then treated with equal volume of nano-Glo HiBiT lytic buffer following manufacture manual (catalog: Promega 3040), mixed for 10 min at 600 rpm in RT and protected from light. Luminescence signal was read out on Ensight.
[0363] For data analysis, low control (culture medium only) was used as blank and subtracted from all other signals. % DMSO was calculated by normalizing compound-treated wells over Page 162 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO DMSO-treated wells, and four-point parameter logistic model was used for dose response curve fitting with software Xlfit. QC parameters: Z’ factor>0.6, DMSO wells %CV<10%, and DMSO / low control>600-fold.
[0364] The IRF5 HiBiT degradation results are shown in the table below. The letter codes for DC50 (nM) include: A (<1 nM); B (1 - 10 nM); C (> 10 - 100 nM); D (> 100 - 1000 nM); E (> 1000 nM); and F (not tested).Table 9. IRF5 HiBit DegradationINCORPORATION BY REFERENCE
[0365] All publications and patents mentioned herein are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.EQUIVALENTS
[0366] While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the present disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
[0367] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described herein. Such equivalents are intended to be within the scope of the following claims.Page 163 of 206IPTS / 200423748.1
Claims
Attorney Docket No.: KME-320WO CLAIMSWhat is claimed:
1. A compound of F ormula A:Formula A,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is -C(O)-, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z3is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each RZ5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;Page 164 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or,. - J &&,,wherein > represents a bond teach Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of W1, W2, and W3is, independently, CRW, N, or, whereinrepresents a bondeach Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selectedPage 165 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO from nitrogen, oxygen, and sulfur, wherein R ' is unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e is 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 166 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lx1and Lx2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from C1-C6alkylene, C2-C6alkenylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, Lr2, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5. or 6 RR;each Rxis, independently, selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclicPage 167 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2- or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring A is a ring selected from phenylenyl, naphthylenyl, pyridinylenyl,Page 168 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-C6 alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-Ce alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, orPage 169 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
2. A compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl):Z2is NRZ2or CRZ'R / 4;each of Z3, Z4, and Z3is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 170 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, orC1&&each Rvis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-C6haloalkyl;each of W1, W2, and W3is, independently, CRW, N, or&&, wherein&&&represents a bondeach Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Page 171 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;eis 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 172 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lx1and Lx2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, Lr2, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and L13is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Page 173 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of C1-C6 alkyl and Ci-C6 haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-C6 alkyl, and Ci-Ce haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:X1is a bivalent moiety selected from -CH2-or -C(O)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Page 174 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WORing B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, - SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2, -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached form 3-6 membered carbocyclylene:each RAis, independently, selected from Ci-Ce alkyl, C2-Ce alkenyl, C2-Ce alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen,Page 175 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
3. A compound of Formula II:or a pharmaceutically acceptable salt thereof, wherein:Page 176 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- Ce alkyl);Z1is -C(O)-, Z2is O, and represents a single bond,or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY;each Rz5is, independently, selected from the group consisting of hydrogen, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each of V1, V2, V3, and V4is, independently, CRV, N, or&&,each Rvis, independently, selected from the group consisting of hydrogen, halo, C1-C6 alkyl, and Ci-Ce haloalkyl;Page 177 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO C — &&&. - j &&& each of W1, W2, and W3is, independently, CRW, N, or1, wherein >represents a bondeach Rwis, independently, selected from the group consisting of hydrogen, halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, C1-C6 alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e is 0, 1, 2, 3, 4, 5, or 6;L is selected from the group consisting of:Page 178 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOeach of Lxland L2is, independently, -O- or -NRX-;each of Lcl, Lc2, Lc3, and Lc4is, independently, selected from Ci-Ce alkylene, C2-C6 alkenylene,C2-C6 alkynylene,wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc;each of Lrl, L12, Lr3, and Lr4is, independently, selected from phenylene, 3-8 membered monocyclic carbocyclylene, 5-14 membered bridged bicyclic carbocyclylene, 5-14 membered spirocyclic carbocyclylene, 3-8 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3-8Page 179 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-14 membered bridged bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of L11, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR;each Rxis, independently, selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)Rxa;each Rcis, independently, selected from the group consisting of halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rca, -ORcb, and -N(RCC)2, or two Rcgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each RRis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), -C(O)Rra, -ORrb, and -N(Rrc)2, or two RRgroups on the same atom, together with the atom to which both are attached, form oxo, 3-6 membered monocyclic carbocyclyl, or 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rxais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;each Rcais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rcbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;each Rccis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rrbis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 180 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO each Rrcis, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-C6haloalkyl;LBM, an E3 ubiquitin ligase binding moiety, is a compound of formula I-aa-1:I-aa-1X1is a bivalent moiety selected from -CH2-or -C(0)-;X2is N or CH;L1is a covalent bond or a C1-3 bivalent hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(S)-, -CR2-, -CF2-, - NR-, -O-, -S-, or -S(O)2;Ring B is a fused ring selected from benzo, 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 6 memberedPage 181 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R1is independently RA, halogen, -CN, -NO2, -OR, -SR, -NR2, -SiR3, -S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, - CR2N(R)C(O)R, -CR2N(R)C(O)NR2, -CFR2, -CF2R, -CF3, -CR2(OR), - CR2(NR2), -OC(O)R, -OC(O)NR2. -OP(O)R2, -OP(O)(OR)2, -OP(O)(OR)NR2, - OP(O)(NR2)2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2J-N(R)S(O)2R, - N(R)P(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)NR2, -N(R)P(O)(NR2)2, or - N(R)S(O)2R, ortwo R1groups together with the atom to which each is attached fomr 3-6 membered carbocyclylene;each RAis, independently, selected from Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3- 10 membered saturated or partially unsaturated carbocyclyl, 3-10 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is, independently, selected from hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, 3-7 membered saturated or partially unsaturated carbocyclyl, 3-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, ortwo R groups on the same carbon or nitrogen are taken together with their intervening atoms to form 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic heterocyclyl having 0-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, -OC1-6 alkyl, -OC3-6 cycloalkyl, or -OC1-6 haloalkyl; andm is 0, 1, 2, 3 or 4.
4. The compound of claim 1, wherein Z1is -C(O)-, Z2is NRZ2or CRZ3RZ4, and represents a single bond.Page 182 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 5. The compound of claim 1, 2, or 4, wherein Z2is NRZ2.
6. The compound of claim 1, 2, or 4, wherein Z2is CRZiRZ4.
7. The compound of claim 1 or 3, wherein Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond.
8. The compound of claim 1 or 3, wherein Z1is N, Z2is CRZ3, and = represents a double bond.
9. The compound of any one of claims 1 to 8, wherein RZ1is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci-Ce alkyl).
10. The compound of any one of claims 1 to 8, wherein RZ1is selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl.
11. The compound of any one of claims 1 to 8, wherein RZ1is Ci-Ce alkyl.
12. The compound of any one of claims 1 to 8, wherein RZ1is selected from the group consisting of II and Ci-Ce alkyl.
13. The compound of claim 12, wherein RZ1is H, -Me, -Et, -nPr, - Pr, -nBu, -Bu, -sBu, or -lBu.
14. The compound of claim 13, wherein RZ1is H, -Me, or -Et.
15. The compound of claim 14, wherein RZ1is H or -Me.
16. The compound of any one of claims 1 to 15, wherein Z2is NRZ2.
17. The compound of claim 16, wherein RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
18. The compound of claim 16, wherein RZ2is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.Page 183 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 19. The compound of claim 16, wherein RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
20. The compound of claim 19, wherein RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.
21. The compound of claim 20, wherein RZ2is cyclopropyl, cyclobutyl, or oxctanyl.
22. The compound of claim 21, wherein RZ2is,,.
23. The compound of any one of claims 1 to 15, wherein Z2is CRZ3RZ4.
24. The compound of claim 23, wherein RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
25. The compound of claim 23, wherein RZ3is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
26. The compound of claim 23, wherein RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.
27. The compound of claim 23, wherein RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.
28. The compound of claim 27, wherein RZ3is cyclopropyl, cyclobutyl, or oxetanyl.
29. The compound of claim 28, wherein RZ3is is,,.
30. The compound of claim 23, wherein R74is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY.Page 184 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 31. The compound of claim 30, wherein RZ4is selected from the group consisting of H, Ci-C6alkyl, and -(Ci-Ce alkyl)-RY.
32. The compound of claim 31, wherein RZ4is selected from the group consisting of II and Ci-Ce alkyl.
33. The compound of claim 32, wherein RZ4is H, -Me, -Et, -nPr, -lPr, -nBu, -Bu, -sBu, or -lBu.
34. The compound of claim 33, wherein RZ4is H, -Me, or -Et.
35. The compound of claim 34, wherein RZ4is H or -Me.
36. The compound of claim 23, wherein RZ3and RZ4are taken together with the carbon atom to which each is attached form 3-8 membered monocyclic carbocyclylene.
37. The compound of claim 36, wherein RZ3and RZ4are taken together with the carbon atom to which each is attached form 3-6 membered monocyclic carbocyclylene.
38. The compound of claim 37, wherein RZ3and RZ4are taken together with the carbon atom to which each is attached form cyclopropylene or cyclobutylene.
39. The compound of any one of claims 1 to 38, wherein Z3is CRZ5.
40. The compound of any one of claims 1 to 39, wherein Z4is CRZ5.
41. The compound of any one of claims 1 to 40, wherein Z5is CRZ5.
42. The compound of any one of claims 1 to 41, wherein each RZ3is, independently, selected from the group consisting of hydrogen, Ci-Ce alkyl, and Ci-Ce haloalkyl.
43. The compound of claim 42, wherein each Rz5is, independently, selected from the group consisting of hydrogen and Ci-Ce alkyl.
44. The compound of claim 43, wherein each Rz5is, independently, H, -Me, -Et, -nPr, -'Pr, -nBu, - Bu, -sBu, or - Bu.
45. The compound of claim 44, wherein each Rz5is, independently, H, -Me, or -Et.
46. The compound of claim 45, wherein each Rz5is, independently, H or -Me.Page 185 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 47. The compound of any one of claims 1 to 46, wherein V2is CRV48. The compound of any one of claims 1 to 47, wherein V4is CRV.
49. The compound of any one of claims 1 to 48, wherein the compound is of Formula I- A:Formula I- A,or a pharmaceutically acceptable salt thereof,50. The compound of any one of claims 1 to 49, wherein each Rvis, independently, selected from the group consisting of hydrogen and Ci-Ce alkyl.
51. The compound of claim 50, wherein each Rvis, independently, H, -Me, -Et, -nPr, - 'Pr, -nBu, -Bu, -sBu, or -Bu.
52. The compound of claim 51, wherein each Rvis, independently, H, -Me, or -Et.
53. The compound of claim 52, wherein each Rvis, independently, H or -Me.
54. The compound of claim 53, wherein each Rvis H.
55. The compound of any one of claims 1 to 54, wherein W1is CRW.
56. The compound of any one of claims 1 to 55, wherein W2is CRW.Page 186 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 57. The compound of any one of claims 1 to 56, wherein each Rwis, independently, selected from the group consisting of hydrogen and Ci-Ce alkyl.
58. The compound of claim 57, wherein each Rwis, independently, II, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -‘Bu.
59. The compound of claim 58, wherein each Rwis, independently, H, -Me, or -Et.
60. The compound of claim 59, wherein each Rwis, independently, H or -Me.
61. The compound of claim 60, wherein each Rwis H.
62. The compound of any one of claims 1 to 61, wherein W3is N.
63. The compound of any one of claims 1 to 61, wherein each R11is, independently, selected from the group consisting of II and Ci-Ce alkyl.
64. The compound of claim 63, wherein each R11is, independently, H, -Me, -Et, -“Pr, -'Pr, -nBu, - Bu, -sBu, or -lBu.
65. The compound of claim 64, wherein each R11is, independently, H, -Me, or -Et.
66. The compound of claim 65, wherein each R11is, independently, H or -Me.
67. The compound of any one of claims 1 to 66, wherein each R22is, independently, selected from the group consisting of H and Ci-Ce alkyl.
68. The compound of claim 67, wherein each R22is, independently, H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -‘Bu.
69. The compound of claim 68, wherein each R22is, independently, H, -Me, or -Et.
70. The compound of claim 69, wherein each R22is, independently, H or -Me.
71. The compound of any one of claims 1 to 70, wherein n is 1, 2, or 3.
72. The compound of claim 71, wherein n is 1 or 2.
73. The compound of claim 72, wherein n is 1.
74. The compound of any one of claims 1 to 73, wherein Ring E is phenyl.Page 187 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO 75. The compound of any one of claims 1 to 73, wherein Ring E is 3-8 membered monocyclic carbocyclyl.
76. The compound of claim 75, wherein Ring E is 3-6 membered monocyclic carbocyclyl.
77. The compound of claim 76, wherein Ring E is 6 membered monocyclic carbocyclyl.
78. The compound of claim 77, wherein Ring E is cyclohexanyl.
79. The compound of any one of claims 1 to 78, wherein each REis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl.
80. The compound of claim 79, wherein each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -*Pr, -nBu, -'Bu, -SBU, -‘BU, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
81. The compound of claim 80, wherein each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -‘Pr, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
82. The compound of any one of claims 1 to 81, wherein e is 0, 1, 2, 3, or 4.
83. The compound of claim 82, wherein e is 2.
84. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-B to Formula I-I:Page 188 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 189 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof.
85. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-B- 1 to Formula I-B-6:Page 190 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 191 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof.
86. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-C- 1 to Formula I-C-5:Page 192 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-C-5,or a pharmaceutically acceptable salt thereof.
87. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-D- 1 to Formula I-D-5:Page 193 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 194 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-D-5,or a pharmaceutically acceptable salt thereof.
88. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-H- 1 to Formula I-H-4:Page 195 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-H-3, Formula I-H-4, or a pharmaceutically acceptable salt thereof.
89. The compound of claim 1 or 2, wherein the compound is of any one of Formula I-G- 1 to Formula I-G-7:Formula I-G-l, Formula I-G-2,Page 196 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 197 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula I-G-7,or a pharmaceutically acceptable salt thereof.
90. The compound of claim 1 or 3, wherein the compound is of Formula II-A:Formula II-A,or a pharmaceutically acceptable salt thereof.
91. The compound of claim 1 or 3, wherein the compound is of any one of any one of Formula II-B to Formula II-J:Page 198 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 199 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOPage 200 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOFormula II-J,or a pharmaceutically acceptable salt thereof.
92. The compound of claim 1 or 3, wherein the compound is of any one of Formula II- B-l to Formula II-B-6:Formula II-B-1, Formula II-B-2,Page 201 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOor a pharmaceutically acceptable salt thereof.
93. The compound of any one of claims 1 to 92, wherein L is selected from the groupPage 202 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WOwherein L comprises at least one 6-membered monocyclic heterocyclylene having 1 -3 nitrogen atoms.
94. The compound of any one of claims 1 to 92, wherein L is selected from the groupwherein L comprises at least one 6-membered monocyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
95. The compound of any one of claims 1 to 94, wherein each of Lcl, Lc2, and Lc3is, independently, selected from Ci-Ce alkylene and C2-C6 alkynylene,wherein each each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc.
96. The compound of claim 95, wherein each of Lcl, Lc2, and Lc3is Ci-Ce alkylene, wherein each of Lcl, Lc2, and Lc3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 Rc.
97. The compound of any one of claims 1 to 96, wherein each Rcis, independently, selected from halo, Ci-Cr> alkyl, and Ci-Ce haloalkyl.
98. The compound of claim 97, wherein each Rcis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -Pr, -nBu, -'Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
99. The compound of any one of claims 1 to 98, wherein each of Lrl, L12, and Lr3is, independently, selected from 3-8 membered monocyclic carbocyclylene, 3-8 memberedPage 203 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO monocyclic heterocyclylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-14 membered spirocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and Lr3is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR.
100. The compound of claim 99, wherein each of Lrl, I.1'2, and Lr3is, independently, selected from 3-8 membered monocyclic carbocyclylene and 3-8 membered monocyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein each of Lrl, L12, and L13is, independently, unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 RR.
101. The compound of any one of claims 1 to 100, wherein each RRis, independently, selected from halo, Ci-G> alkyl, and Ci-Ce haloalkyl.
102. The compound of claim 101, wherein each RRis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -Pr, -nBu, -‘Bu, -sBu, -‘Bu, -CF3. -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or -CH2CF3.
103. The compound of any one of claims 1 to 102, wherein L1is absent.
104. The compound of any one of claims 1 to 103, wherein Ring A and its R1substituents105. The compound of any one of claims 1 to 104, wherein Ring B is benzo.
106. The compound of any one of claims 1 to 105, wherein each R1is, independently, selected from the group consisting of Ci-Ce alkyl, halogen, and -OR, orPage 204 of 206IPTS / 200423748.1Attorney Docket No.: KME-320WO two R1groups together with the atom to which each is attached form cyclopropylene or cyclobutylene.
107. A compound of Table 1, or a pharmaceutically acceptable salt thereof.
108. A pharmaceutical composition comprising a compound of any one of claims 1 to 107, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient thereof.
109. A method of degrading IRF5 in a subject or biological sample, the method comprising administering to said subject or contacting said biological sample with a compound of any one of claims 1 to 107 or a pharmaceutical composition of claim 108.
110. A method of treating an IRF5-mediated disorder, disease, or condition in a subject in need thereof, the method comprising administering to said subject a compound of any one of claims 1 to 107 or a pharmaceutical composition of claim 108.
111. The method of claim 110, wherein the IRF5-mediated disorder, disease, or condition is an autoimmune disease.
112. The method of claim 111, wherein the IRF5-mediated disorder, disease, or condition is selected from ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, vasculitis, inflammatory bowel disease, juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, psoriatic arthritis, sclerosing cholangitis, Sjogren syndrome, cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), systemic scleroderma, Type 1 diabetes mellitus, ulcerative colitis, macrophage activation syndrome (MAS), multiple sclerosis (MS), primary biliary cirrhosis (PBC), myocardial inflammation, and atherosclerosis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is systemic lupus erythematosus (SLE).Page 205 of 206IPTS / 200423748.1
